Chapter 100

References

  1. Abdelmagid OY, Larson L, Payne L, et al. 2004. Evaluation of the efficacy and duration of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges. Vet Ther 5:173-186.
  2. Ackerman O, Dorr W. 1983. Prufung der Schutzdauer gege die Panleukopenie der Katze nach Impfung mit Felidovac P. Die Blauned Hefte 66:263-267.
  3. Addie D, Belak S, Boucraut-Baralon C, et al. 2009. Feline infectious peritonitis. ABCD guidelines on prevention and management. J Feline Med Surg 11:594-604.
  4. Addie DD, Jarrett O, Simpson J, et al. 1996. Feline parvovirus in pedigree kittens. Vet Rec 138:119.
  5. Addie DD, Toth S, Thompson H, et al. 1998. Detection of feline parvovirus in pedigree kitten mortality. Vet Rec 142:353-356.
  6. Aeffner F, Ulrich R, Schulze-Rickamp L, et al. 2006. Cerebellar hypoplasia in three sibling cats after intrauterine or early postnatal parvovirus infection. Dtsch Tierarztl Wochenschr 113:403-406.
  7. Aguiar JC, Hedstrom RC, Rogers WO. 2002. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 20:275-280.
  8. Akita GY, Ianconescu M, MacLachlan NJ, et al. 1994. Bluetongue disease in dogs associated with contaminated vaccine. Vet Rec 134:283-284.
  9. 8a. Almberg ES, Cross PC, Mech LD, et al. 2011. Infectious diseases in Yellowstone's canid community. Yellowstone Science 19:16-24.
  10. Al-Sarraf R. 1998. Update on feline vaccine-associated fibrosarcomas. Vet Med 93(8):729-732.
  11. Alving CR. 2002. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 20:S56-S64.
  12. An DJ, Jeong W, Hey-Young J, et al. 2011. Phylogenetic analysis of feline panleukopenia virus (FLPV) strains in Korean cats. Res Vet Sci 90:163-167.
  13. Anderson KA, Brooks AS, Morrison AL, et al. 2004. Impact of Giardia vaccination on asymptomatic Giardia infections in dogs at a research facility. Can Vet J 45:924-930.
  14. Andre-Fontaine G. 2006. Canine leptospirosis—do we have a problem? Vet Microbiol 117:19-24.
  15. Andre-Fontaine G, Branger C, Gray AW, et al. 2003. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Vet Rec 153:165-169.
  16. Animal and Plant Health Inspection Service. 2011. http:/www./aphis.usda.gov. Accessed 3/11/11.
  17. Deshpande MS, Jirjis FF, Tubbs AL. 2009. Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther 10:103-112.
  18. Anonymous. 1993. Update on cat vaccines. BVA Congress. Vet Rec 133:409-411.
  19. Anonymous. 1997. Is annual revaccination of pets appropriate? Aust Vet J 75:400-401.
  20. Anonymous. 1997. Rabies and quarantine: report of the BVA working group. Vet Rec 141:79-81.
  21. Anonymous. 1998. 1998 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines. J Am Vet Med Assoc 212:241.
  22. Anonymous. 1999. Canine vaccinations proposed for wolves, wolf hybrids. J Am Vet Med 215:1226.
  23. Anonymous. 2000. How frequently should dogs and cats be vaccinated? J Small Anim Pract 41:277.
  24. Anonymous. 2000. How frequently should dogs and cats be vaccinated? Vet Rec 146:449-450.
  25. Anonymous. 2001. Feline vaccine liability and management, American Association of Feline Practitioners/Academy of Feline Medicine. Compend Contin Educ Pract Vet 23:116-127.
  26. Anonymous. 2001. Merial voluntarily recalls canine vaccines. Vet Pract News.
  27. Anonymous. 2001. Principles of vaccination. J Am Vet Med Assoc 219:575-576.
  28. Anonymous. 2002. Deluge of questions prompts AAFP to develop FIV vaccine brief. J Am Vet Med Assoc 221:1231-1234.
  29. Anonymous. 2003. CVMP advice on injection-site fibrosarcomas in cats. Vet Rec 152:381-382.
  30. Anonymous. 2003. Government response on cat and dog vaccination. Vet Rec 152:35-36.
  31. Anonymous. 2005. Compendium of Animal Rabies Prevention and Control. J Am Vet Med Assoc 226(8):1304-1310.
  32. Anonymous. 2006. Challenges of vaccination (Oct 21) [Brochure, BVA Congress]. Vet Rec 159:540-541.
  33. Anonymous. 2007. Compendium of animal rabies prevention and control. J Am Vet Med Assoc 230(6):833-840.
  34. Anonymous. 2008. What you should know about vaccinations. Caring for animals today tomorrow always. http://www.avma.org. Printed 6/08.
  35. Anonymous. 2011. Public health response to a rabid dog in an animal shelter—North Dakota and Minnesota, 2010. MMWR 59(51 & 52):1678-1681.
  36. Appel MJ. 1999. Forty years of canine vaccination. Adv Vet Med 41:309-324.
  37. Appel MJG, Paoeletti E. 1988. Immune response to vaccinia virus and recombinant virus products in dogs. Am J Vet Res 49:1932-1934.
  38. Arai M, Darmen J, Lewis A, et al. 2000. The use of human hematopoietic growth factors (rhGM-CSF and rhEPO) as a supportive therapy for FIV-infected cats. Vet Immunol Immunopathol 77:71-92.
  39. Arikawa J. 2010. Symposium III report. Current status of veterinary vaccines. Vaccine 28:8034-8035.
  40. Auby JC, Chappuis G, Desmettre P, et al. 1974. Vaccination of dogs. Duration of immunity of distemper and infectious canine hepatitis. Rec Med Vet 150:33-36.
  41. Australian Government Quarantine and Inspection Service. 2011. Importation regulations. http://www.daff.gov.au/aqis/cat-dogs/countries/cat4/info-pack-4. Accessed 3/11/11.
  42. Babiuk LA, Babiuk SL, Loehr BI, et al. 2000. Nucleic acid vaccines: research tool or commercial reality. Vet Immunol Immunopathol 76:1-23.
  43. Babiuk LA, van Drunen Littel-van den Hurk, Babiuk SL. 1999. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopathol 72:189-202.
  44. Baer GM. 1997. Evaluation of an animal rabies vaccine by use of two types of potency tests. Am J Vet Res 58:837-840.
  45. Baer GM, Brooks RC, Foggin CM. 1989. Oral vaccination of dogs fed canine adenovirus in baits. Am J Vet Res 50:836-837.
  46. Baker JA, Robson DS, Gillespie JH, et al. 1959. A nomograph that predicts the age to vaccinate puppies against distemper. Cornell Vet 49:158-167.
  47. Baker RJ. 1998. Feline fibrosarcomas in vaccination sites. Feline Pract 26:18-20.
  48. Banse HE, McKenzie EC, Nelson Jr S. 2008. Assessment of serum antibody titers against canine distemper virus, canine adenovirus type II, and canine parvovirus in Alaskan sled dogs before and after a long-distance race. J Am Vet Med Assoc 232:1669-1673.
  49. Banyard MR. 1998. Prevalence of intercurrent disease in dogs and cats presented for vaccination at a veterinary practice. Aust Vet J 76:600-601.
  50. Banyard MR. 1998. Prevalence of intercurrent disease in dogs and cats presented for vaccination at a veterinary practice. Aust Vet J 76:600-601.
  51. Barlow WE, Davis RL, Glasser JW, et al. 2001. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 345:656-661.
  52. Barnard BJH, Geyer DHJ, DeKoker WC. 1977. Neurological symptoms in a cat following vaccination with high-egg passage Flury rabies vaccine of chicken embryo origin. Onderstepoort J Vet Res 44:195-196.
  53. Barr CS, McDonough PL, Scipioni-Ball R, et al. 2005. Serologic responses of dogs given a commercial vaccine against Leptospira interrogans serovar pomona and Leptospira kirschneri serovar grippotyphosa. Am J Vet Res 66:1780-1784.
  54. Barrell EA, Pecoraro HL, Torres-Henderson C, et al. 2010. Seroprevalence and risk factors for canine H3N8 influenza virus exposure in household dogs in Colorado. J Vet Intern Med 24:1524-1527.
  55. Becker AM, Janik TA, Smith EK, et al. 1989. Propionibacterium acnes immunotherapy in chronic recurrent canine pyoderma. J Vet Intern Med 3:26-30.
  56. Bellinger DA, Chang J, Bunn TO, et al. 1983. Rabies induced by high-egg passage Flury strain vaccine. J Am Vet Med Assoc 183:997-998.
  57. Belshe RB, Stevens C, Gorse GJ, et al. 2001. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher-and lower-risk volunteers. J Infect Dis 183:1343-1352.
  58. Bender SC, Bergman DL, Wenning KM, et al. 2009. No adverse effects of simultaneous vaccination with the immunocontraceptive GonaConTM and a commercial rabies vaccine on rabies virus neutralizing antibody production in dogs. Vaccine 27:7210-7213.
  59. Bensignor E. 1999. What is your diagnosis? Post-rabies-vaccination alopecia. J Small Anim Pract 40:151-189.
  60. Bergman JG, Muniz M, Sutton D, et al. 2006. Comparative trial of the canine parvovirus, canine distemper virus and canine adenovirus type 2 fractions of two commercially available modified live vaccines. Vet Rec 159:733-736.
  61. Bergman P. 1998. Etiology of feline vaccine-associated sarcomas: history and update. J Am Vet Med Assoc 213:1424-1425.
  62. Bergman P. 2000. Recent advances in the treatment of feline vaccine-associated sarcomas. Adv Small Anim Med Surg 13:1-2
  63. Bergman P, Hendrick MJ, Macy D, et al. 1999. Feline sarcoma and vaccination. Vet Forum Mar:40-47.
  64. Berkelman RL. 2003. Human illness associated with use of veterinary vaccines. Clin Infect Dis 37:407-414.
  65. Berndtsson LT, Nyman AKJ, Rivera E, et al. 2011. Factors associated with the success of rabies vaccination of dogs in Sweden. Acta Vet Scand 53:22.
  66. Bienzle D, Reggeti F, Wen X, et al. 2004. The variability of serological and molecular diagnosis of feline immunodeficiency virus infection. Can Vet J 45:753-757.
  67. Blancou J, Milward F, Toma B. 1981. Vaccination against rabies in carnivores treated with corticoids. Rec Med Vet 157:651-657.
  68. Blanton JD, Palmer D, Rupprecht CE. 2010. Public veterinary medicine: public health: rabies surveillance in the United States during 2009. J Am Vet Med Assoc 237:646-657.
  69. Blanton JD, Robertson K, Palmer D, et al. 2009. Rabies surveillance in the United States during 2008. J Am Vet Med Assoc 235:676-689.
  70. Blixenkrone-Moller M, Svansson V, Have P, et al. 1993. Studies on manifestations of canine distemper virus infection in an urban dog population. Vet Microbiol 37:163-173.
  71. Bodewes R, Egberink HF. 2009. An update on viral diseases of the dog and cat. Tijdschr Diergeneeskd 134:330-336.
  72. Böhm M, Thompson H, Weir A, et al. 2004. Serum antibody titres to canine parvovirus, adenovirus and distemper virus in dogs in the UK which had not been vaccinated for at least three years. Vet Rec 154:457-463.
  73. Bolcskei A, Bilkei G, Biro O, et al. 1995. Efficacy of the vaccine Primucell FIP and its acceptance by owners-OK as is. Tierarztl Umschau 50:851-853.
  74. Bolt G, Jensen TD, Gottschalck E, et al. 1997. Wild-type distemper viruses differ from vaccine strains. J Gen Virol 78:367-372.
  75. Bonsch C, Kempf C, Ros C. 2008. Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity. J Virol 82:11784-11791.
  76. Borja-Cabrera GP, Correia Pontes NN, da Silva VO, et al. 2002. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20:3277-3284.
  77. Bouchard G, Plata-Madrid H, Youngquist RS, et al. 1992. Absorption of an alternate source of immunoglobulin in pups. Am J Vet Res 53:230-233.
  78. Brearley MJ. 2003. Vaccine-associated feline sarcoma. Vet Rec 152:478.
  79. Brent GS. 1997. Administering intranasal vaccines. Vet Forum Oct:42.
  80. Briggs DJ, Smith JS, Mueller FL, et al. 1998. A comparison of two serological methods for detecting the immune response after rabies vaccination in dogs and cats being exported to rabies-free areas. Biologicals 26:347-355.
  81. Brooks R. 1991. Adverse reactions to canine and feline vaccines. Aust Vet J 68:342-344.
  82. Brower AI, Radi C, Toohey-Kurth K. 2004. Feline panleukopenia: a diagnostic laboratory's perspective. Vet Med 99:714-721.
  83. Brown CC, Rhyan JC, Grubman MJ, et al. 1996. Distribution of bluetongue virus in tissues of experimentally infected pregnant dogs as determined by in situ hybridization. Vet Pathol 33:337-340.
  84. Brunner C, Kanellos T, Meli M, et al. 2006. Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with a chlamydial component. Vaccine 24:1838-1846.
  85. Bryskier A. 2000. Novelties in the field of anti-infective compounds in 1999. Clin Infect Dis 31:1423-1466.
  86. Bungiro RD Jr, Greene J, Kruglov E, et al. 2001. Mitigation of hookworm disease by immunization with soluble extracts of Ancylostoma ceylanicum. J Infect Dis 183:1380-1387.
  87. Buonavoglia C, Cavalli A, Gravino E, et al. 1994. Intranasal vaccination of pups with maternally derived antibodies with a modified live canine parvovirus. J Vet Med B 41:3-8.
  88. Buonavoglia C, Marsilio F, Tempesta M, et al. 1993. Use of a feline panleukopenia modified live virus vaccine in cats in the primary stage of feline immunodeficiency virus infection. Zentralbl Veterinarmed B 40:343-346.
  89. Buonavoglia C, Tollis M, Buonavoglia D, et al. 1992. Response of pups with maternal derived antibody to modified-live canine parvovirus vaccine. Comp Immunol Microbiol Infect Dis 15:281-283.
  90. Buracco P, Martano M, Morello E, et al. 2002. Vaccine-associated-like fibrosarcoma at the site of a deep nonabsorbable suture in a cat. Vet J 163:105-107.
  91. Bureau of Animal Health—Australia. 2011. http://animalhealthaustralia.com.au. Accessed 3/11/11.
  92. Burr H, Coyne M, Gay C, et al. 1998. Duration of immunity in companion animals after natural infection and vaccination, Publication SAB9824. Pfizer Animal Health.
  93. Burr P. 2006. Serological testing—an alternative to boosters? Vet Microbiol 117:39-42.
  94. Burr P, Duthie S, Haig KT. 2010. Future of PETS. Vet Rec 166:373.
  95. Burr PD, Snodgrass DR. 2003. Serological response to rabies vaccination for the pet travel scheme (PETS), abstract no. 35. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13–18, Guelph, Ontario, Canada.
  96. Burton G, Mason KV. 1997. Do postvaccinal sarcomas occur in Australian cats? Aust Vet J 75:102-106.
  97. Calderon MG, Romanutti C, D’Antuono A, et al. 2011. Evolution of canine parvovirus in Argentina between years 2003 and 2010: CPV2c has become the predominant variant affecting the domestic dog population. Virus Res 157:106-110.
  98. Camero M, Cavalli A, Bozzo G, et al. 2004. A severe dual infection by feline panleukopenia virus and feline calicivirus in an adult cat. New Microbiol 27:79-82.
  99. Campbell DJ, Rawlings JM, Koelsch S, et al. 2004. Age-related differences in parameters of feline immune status. Vet Immunol Immunopathol 100:73-80.
  100. Carithers D. 1995. Biological and immunogenic properties of canarypox vectored vaccines. Vaccine 13:539-549.
  101. Carithers D. 2004. Recombinant canarypox vector vaccine (product information). Merial Inc., Duluth, GA.
  102. Carlson J, Mackowiak M. 1997. A new vaccine for canine parvovirus type-2:laboratory and field studies (research report). Rhone Merieux, Athens, GA.
  103. Carmichael LE, Greene CE. 1998. Canine herpesvirus infection, pp 28l-232. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  104. Carmichael LE, Jourbet JC, Pollock RVH. 1983. A modified live canine parvovirus vaccine. II. Immune response. Cornell Vet 73:13-29.
  105. Carmichael LE, Robson DS, Barnes FD. 1962. Transfer and decline of maternal infectious canine hepatitis antibody in puppies. Proc Soc Exp Biol Med 109:677-681.
  106. Carmichael LE. 1959. Studies on infectious canine hepatitis. Doctoral dissertation. Cornell University, Ithaca, NY.
  107. Carmichael LE. 1997. Vaccines for dogs, pp 326-335. In Pastoret PP, Blancou J, Vannier P, et al. (eds): Veterinary vaccinology. Elsevier, New York.
  108. Carpenter TE. 2001. Evaluation of effectiveness of a vaccination program against an infectious disease at the population level. Am J Vet Res 62:202-205.
  109. Carpenter TE. 2001. Use of sample size for estimating efficacy of a vaccine against an infectious disease. Am J Vet Res 62:1582-1584.
  110. Carroll EE, Schultz RD. 2003. Phenotypic characterization of feline vaccine site reactions: MHC class II, CD11b, CD3 predominate, abstract no. 63. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13-18, Guelph, Ontario, Canada.
  111. Casadevall A. 2001. Diagnostic and therapeutic antibodies. Clin Infect Dis 32:670-671.
  112. Castro TX, Costa Em, Leite JP, et al. 2011. Monitoring of canine parvovirus (CPV) strains detected in vaccinated puppies in Brazil. Res Vet Sci 90:336-340.
  113. Chalmers WSK. 2006. Overview of new vaccines and technologies. Vet Microbiol 117:25-31.
  114. Chang HW, Ho SY, Lo HF, et al. 2006. Vaccine-associated rhabdomyosarcoma with spinal epidural invasion and pulmonary metastasis in a cat. Vet Pathol 43:55-58.
  115. Chapek ML, Marshall RF, McClaughry LE. 1981. Duration of immunity in dogs inoculated with an inactivated feline parvovirus vaccine. Vet Med Small Anim Clin 76:1319-1324.
  116. Chappuis G. 1998. Neonatal immunity and immunization in early age: lesions from veterinary medicine. Vaccine 16:1468-1472.
  117. Chengalvala MV, Bhat BM, Bhat R, et al. 1994. Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccine in dogs. J Gen Virol 75:125-131.
  118. Cherpillod P, Tipold A, Griot-Wenk M, et al. 2000. DNA vaccine encoding nucleocapsid and surface proteins of wild type canine distemper virus protects its natural host against distemper. Vaccine 18:2927-2936.
  119. Choromanski L, Brown K, Bryant S, et al. 1995. Modified live Toxoplasma gondii (mutant strain) vaccine for cats, pp 137-172. In Proceeding of the American Association of Feline Practice and Academy of Feline Medicine, Washington, DC.
  120. Christine KL. 2008. Personal communication. http://www.germanshepherds.com/forum/members/40086-kris-l-christine.html. Accessed 8/7/11.
  121. Chu HJ, Chavez LG, Blumer BM, et al. 1992. Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. J Am Vet Med Assoc 201:403-411.
  122. Church R. 1989. Lameness in kittens after vaccination. Vet Rec 125:609.
  123. Clark KA, Wilson PJ. 1996. Postexposure rabies prophylaxis and preexposure rabies vaccination failure in domestic animals. J Am Vet Med Assoc 208:1827-1830.
  124. Clark NC, Kushner NN, Barrett CB, et al. 1991. Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection. J Am Vet Med Assoc 199:1433-1443.
  125. Cleaveland A, Kaare M, Knobel D, et al. 2006. Canine vaccination—providing broader benefits for disease control. Vet Microbiol 117:43-50.
  126. Clough NEC, Roth JA. 1995. Methods for assessing cell-mediated immunity in infectious disease resistance and in the development of vaccines. J Am Vet Med Assoc 206:1208-1216.
  127. Coates JR, Carmichael KP, Roberts AW, et al. 1998. Vaccine-associated canine distemper viral encephalomyelitis in 14 dogs. Unpublished observations, University of Georgia, Athens, GA.
  128. Cohen AD, Schoenfeld Y. 1996. Vaccine-induced autoimmunity. J Autoimmun 9:699-703.
  129. Cohen M, Wright JC, Brawner WR, et al. 2001. Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996–2000). J Am Vet Med Assoc 219:1582-1589.
  130. Committee for Veterinary Medical Products. 2003. Available at http://www.emea.europa.eu/dpfs/vet/press/pp/020503en.pdf.
  131. Confavreux C, Suissa S, Saddier P, et al. 2001. Vaccination and the risk of relapse in multiple sclerosis. N Engl J Med 344:319-326.
  132. Connell S. 2003. Manufacturer addresses concerns about FIV vaccine. J Am Vet Med Assoc 222:149.
  133. Cooper PE, Chappuis G, Saint-Gerand AL, et al. 1991. Comparison of the efficiency of different vaccines of dogs, utilizing monovalent or combination forms, with serologic and challenge studies at 12, 22 and 26 months after vaccination. Bull Mens Soc Vet Prat Fr 75:131-152.
  134. Cormie J, Cormie H. 2010. Reporting vaccine failures as suspected adverse reactions. Vet Rec 167:263-264.
  135. Cornwell HJC, Thompson H. 1982. Vaccination in the dog. In Pract 4:151-155.
  136. Couto CG, Macy DW. 1998. Review of treatment options for vaccine-associated feline sarcoma. J Am Vet Med Assoc 213:1426-1427.
  137. Couto SS, Griffey SM, Duarte PC, et al. 2002. Feline vaccine-associated fibrosarcoma: morphologic distinctions. Vet Pathol 39:33-41.
  138. Cox WI. 1988. Examining the immunological hemopoietic properties of an immunostimulant. Vet Med 83:424-428.
  139. Coyne MJ, Burr HH, Yule TD, et al. 2001. Duration of immunity in dogs after vaccination or naturally acquired infection. Vet Rec 149:509-515.
  140. Coyne MJ, Burr HH, Yule TD, et al. 2001. Duration of immunity in cats after vaccination or naturally acquired infection. Vet Rec 149:545-548.
  141. Coyne MJ. 2000. Comparing combination vaccines for CPV and CDV. J Am Anim Hosp Assoc 36:137-142.
  142. Coyne MJ. 2000. Seroconversion of puppies to canine parvovirus and canine distemper virus: a comparison of two combination vaccines. J Am Anim Hosp Assoc 36:137-142.
  143. Coyne MJ, Postorino-Reeves NC, Rosen DK. 1997. Estimated prevalence of injection site sarcomas in cats during 1992. J Am Vet Med Assoc 210:249-251.
  144. Crawford PC, Hanel RM, Levy JK. 2003. Evaluation of treatment of colostrum-deprived kittens with equine IgG. Am J Vet Res Aug;64:969-975.
  145. Crawford PC, Levy JK, Werner LL. 2006. Evaluation of surrogate markers for passive transfer of immunity in kittens. J Am Vet Med Assoc 228:1038-1041
  146. Crawford PC, Slater MR, Levy JK. 2005. Accuracy of polymerase chain reaction assays for diagnosis of feline immunodeficiency virus infection in cats. J Am Vet Med Assoc 2005 May 1;226:1503-1507.
  147. Cummins JM, Tompkins MB, Olsen RC. 1988. Oral use of human alpha interferon in cats. J Biol Respir Mod 7:513-523.
  148. Datz CA. 2010. Noninfectious causes of immunosuppression in dogs and cats. Vet Clin Small Anim 40:459-467.
  149. David D, Bellaiche M, Yakobson BA. 2010. Rabies in two vaccinated dogs in Israel. Vet Rec 167:907-908.
  150. Davies DH, Pidford S. 1991. Vaccination of dogs with multi-component vaccines. Aust Vet J 68:183-184.
  151. Davis R. 2000. Vaccine extraimmunization—too much of a good thing? JAMA 283:1339-1340.
  152. Davis KM, Hardie EM, Martin FR, et al. 2007. Correlation between perioperative factors and successful outcome in fibrosarcoma resection in cats. Vet Rec 161:199-200.
  153. Davis-Wurzler, GM. 2006. Current vaccination strategies in puppies and kittens. Vet Clin Small Anim 36:607-640.
  154. Dawson S, Gaskell RM. 1993. Problems with respiratory virus vaccination in cats. Compend Contin Educ Pract Vet 15:1347-1369.
  155. Dawson S, McArdle F, Bennett D, et al. 1993. Investigation of vaccine reactions and breakdowns after feline calicivirus vaccination. Vet Rec 132:346-350.
  156. Dawson S, Willoughby K, Gaskell RM et al. 2001. A field trial to assess the effect of vaccination against feline herpesvirus, feline calicivirus and feline panleucopenia virus in 6-week-old kittens. J Feline Med Surg 3:17-22.
  157. Day CEI. 1987. Isopathic prevention of kennel cough. Is vaccination justified? Faringdon, Oxon, UK.
  158. Day MJ. 2006. Vaccine side effects: fact and fiction. Vet Microbiol 117:51-58.
  159. Day MJ. 2007. Immune system development in the dog and cat. J Comp Pathol 137:S10-S15.
  160. Day MJ. 2007. Vaccine safety in the neonatal period. J Comp Pathol 137:S51-S56.
  161. Day MJ. 2010. Ageing, immunosenescence and inflammageing in the dog and cat. J Comp Pathol 142(Suppl 1):S60-S69.
  162. Day MJ, Horzinek MC, Schultz RD. 2007. Guidelines for the vaccination of dogs and cats. J Small Anim Pract 48:528-541.
  163. Day MJ, Horzinek MC, Schultz RD. 2010. Guidelines for the vaccination of dogs and cats. J Small Anim Pract 51:1-32.
  164. Day MJ, Horzinek MC, Schultz RD. 2010. Guidelines for the vaccination of dogs and cats. Compiled by the vaccination guidelines group of the World Small Animal Veterinary Association. J Small Anim Pract 51:338-356.
  165. Day MJ, Schoon HA, Magnol JP, et al. 2007. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine 25:4073-4084.
  166. De Amorim IFG, Freitas E, Alves CF, et al. 2010. Humoral immunological profile and parasitological statuses of Leishmune vaccinated and visceral leishmaniasis infected dogs from an endemic area. Vet Parasitol 173:55-63.
  167. Decaro N, Buonavoglia D, Desario C, et al. 2010. Characterisation of canine parvovirus strains isolated from cats with feline panleukopenia. Res Vet Sci 89:275-278.
  168. DeBoer DJ, Moriello KA, Blum JL, et al. 2002. Safety and immunologic effects after inoculation of inactivated and combined live-inactivated dermatophytosis vaccines in cats. Am J Vet Res 63:1532-1537.
  169. DeBoer DJ, Moriello KA, Thomas CB, et al. 1990. Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent superficial pyoderma in dogs. Am J Vet Res 51:636-639.
  170. Decaro N, Desario C, Elia G, et al. 2007. Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: a clinical and laboratory diagnostic dilemma. Vaccine 25:1161-1166.
  171. Decaro N, Pratelli A, Campolo M, et al. 2004. Quantitation of canine coronavirus RNA in the faeces of dogs by TaqMan RT-PCR. J Virol Methods 119:145-150.
  172. Decaro N, Pratelli A, Tinelli A, et al. 2004. Fecal immunoglobulin A antibodies in dogs infected or vaccinated with canine coronavirus. Clin Diagn Lab Immunol 11:102-105.
  173. De Cramer KGM, Stylianides E, van Vuuren M. 2011. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus. Vet Microbiol 149:126-132.
  174. De Jong MCM, Bouma A. 2001. Herd immunity after vaccination: how to quantify it and how to use it to halt disease. Vaccine 19:2722-2728.
  175. Delack JB. 2000. Comment regarding revaccination guidelines. Can Vet J 41:168-169.
  176. Demeter Z, Palade EA, Hornyak A, et al. 2010. Controversial results of the genetic analysis of a canine distemper vaccine strain. Vet Microbiol 142:420-426.
  177. Department of Agriculture (Canada). 2011. http://www.agr.gc.ca. Accessed 3/11/11.
  178. Department for Environment, Food and Rural Affairs (Defra). 2011. Traveling with pets. http://ww2.defra.gov.uk/wildlife-pets/pets/travel/. Accessed 3/5/11.
  179. De Serres G, Sciberras J, Naus M, et al. 1999. Protection after two doses of measles vaccine is independent of interval between doses. J Infect Dis 180:187-190.
  180. Deshpande MS, Abdelmagid O, Tubbs A, et al. 2009. Experimental reproduction of canine influenza virus H3N8 infection in young puppies. Vet Ther 10:29-39.
  181. Deshpande MS, Jirjis FF, Tubbs AL. 2009. Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther 10:103-112.
  182. De Turiso JAL, Cortes TE, Martinez C, et al. 1992. Recombinant vaccine for canine parvovirus in dogs. J Virol 66:2748-2753.
  183. Dhama K, Mahendran M, Gupta PK, et al. 2008. DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Commun 32:341-356.
  184. Di Francesco A, Piva S, Baldelli R. 2004. Prevalence of Chlamydophila felis by PCR among healthy pet cats in Italy. New Microbiol 27:199-201.
  185. Dillon CJ, Mauldin N, Baer KE. 2005. Outcome following surgical removal of nonvisceral soft tissue sarcomas in cats: 42 cases (1992–2000). J Am Vet Med Assoc 227:1955-1957.
  186. Dimmitt R. 1991. Clinical experience with cross-protective anti-endotoxin antiserum in dogs with parvoviral enteritis. Canine Pract 16:23-26.
  187. Dittmann S. 2001. Vaccine safety: risk communication-a global perspective. Vaccine 19:2446-2456.
  188. Dodds WJ. 1984. Bleeding diseases of small animals. Vet Ref Lab News 1:1-4.
  189. Dodds WJ. 1995. Vaccine-associated disease in young Weimaraners, p 85. In Proceedings of the Annual Conference of the American Holistic Veterinary Medical Association, Snowmass, CO.
  190. Dodds WJ. 1999. More bumps on the vaccine road. Adv Vet Med 41:715-732.
  191. Dodds WJ. 2002. Assessing the need for booster vaccination. Can Vet J 43:81.
  192. Dodds WJ. 2003. Advocate for serologic testing after vaccination. J Am Vet Med Assoc 222:149-150.
  193. Dougherty SA, Center SA, Shaw EE, et al. 1991. Juvenile onset polyarthritis in Akitas. J Am Vet Med Assoc 198:849-855.
  194. Dubielzig RR, Everitt J, Shadduck JA, et al. 1990. Clinical and morphologic features of post-traumatic ocular sarcomas in cats. Vet Pathol 27:62-65.
  195. Dubielzig RR, Hawkins KL, Miller PE. 1993. Myofibroplastic sarcoma originating at the site of rabies vaccination in a cat. J Vet Diagn Invest 5:637-638.
  196. Dubovi EJ. 1996. When serological testing is not enough: diagnosing disease in vaccinated animals. Semin Vet Med Surg 11:183-186.
  197. Dunham SP. 2006. Lessons from the cat: development of vaccines against lentiviruses. Vet Immunol Immunopathol 112:67-77.
  198. Dunham SP, Bruce J, MacKay S, et al. 2006. Limited efficacy of an inactivated feline immunodeficiency virus vaccine. Vet Rec 158:561-562.
  199. Dunham SP, Flynn JN, Rigby MA, et al. 2002. Protection against feline. Vaccine 20:1483-1496.
  200. Durr S, Mindekem R, Kaninga Y, et al. 2009. Effectiveness of dog rabies vaccination programmes: comparison of owner-charged and free vaccination campaigns. Epidemiol Infect 137:1558-1567.
  201. Duval D, Giger U. 1996. Vaccine-associated immune-mediated hemolytic anemia in the dog. J Vet Intern Med 10:290-295.
  202. Dyer F, Diesel G, Cooles S, et al. 2010. Suspected adverse reactions, 2009. Vet Rec 167:118-121.
  203. Dyer F, Mulugeta R, Spagnuolo-Weaver M, et al. 2005. Suspect adverse reactions, 2004. Vet Rec 156:562-564.
  204. Dyer F, Spagnuolo-Weaver M, Cooles S, et al. 2007. Suspected adverse reactions, 2006. Vet Rec 160:748-750.
  205. Dym M. 1998. Viewpoint on vaccination guidelines and alternative modalities. J Am Vet Med Assoc 213:25-26.
  206. Edinboro CH, Ward MP, Glickman LT. 2004. A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis (kennel cough) in dogs entering a humane shelter. Prev Vet Med 62:89-99.
  207. Edwards BG, Buell DJ, Acree WM. 1977. Evaluation of a new feline rhinotracheitis virus vaccine. Vet Med Small Anim Clin 72:205-209.
  208. Edwards DS, Henley WE, Ely ER, et al. 2004. Vaccination and ill-health in dogs: a lack of temporal association and evidence of equivalence. Vaccine 22(25-26):3270-3273.
  209. Egberink H, Addie D, Belak S, et al. 2009. Bordetella bronchiseptica infection in cats. ABCD guidelines on prevention and management. J Feline Med Surg 11:610-614.
  210. Ek-Kommonen C, Rudback E, Anttila M, et al. 2003. Canine distemper of vaccine origin in European mink, Mustela lutreola—a case report. Vet Microbiol 92:289-293.
  211. Ek-Kommonen C, Sihvonen L, Pekkanen K, et al. 1997. Outbreak of canine distemper in vaccinated dogs in Finland. Vet Rec 141:380-383.
  212. Ellis J. 2008. Canine infectious tracheobronchitis update: epidemiology, pathogenesis, and prophylaxis. Insights Vet Med 6:1-7.
  213. Ellis JA. 1999. Feline vaccination protocol needs further scrutiny. J Am Vet Med Assoc 215:620.
  214. Ellis JA. 1999. More on efficacy of vaccinating cats at 3-year intervals. Am J Vet Res 60:1035-1036.
  215. Ellis JA. 2001. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. J Am Vet Med Assoc 218:367-375.
  216. Ellis JA, Jackson ML, Bartsch RC, et al. 1996. Use of immunohistochemistry and polymerase chain reaction for detection of oncornaviruses in formalin-fixed, paraffin-embedded fibrosarcomas from cats. J Am Vet Med Assoc 209:767-771.
  217. Ellis JA, Krakowka GS, Dayton AD, et al. 2002. Comparative efficacy of an injectable vaccine and an intranasal vaccine in stimulating systemic Bordetella bronchiseptica-reactive antibody responses in seropositive dogs. J Am Vet Med Assoc 220:43-48.
  218. Ellis WA. 2010. Control of canine leptospirosis in Europe: time for a change? Vet Rec 167:602-605.
  219. El-Madhun AS, Cox RJ, Haaheim LR. 1999. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis 180:1356-1360.
  220. Elmslie RE, Dow SW, Ogilvie GK. 1991. Interleukins: biological properties of therapeutic potential. J Vet Intern Med 5:283-293.
  221. Elston T, Rodano I, Flemming D, et al. 1998. 1998 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines. J Am Vet Med Assoc 212:227-241.
  222. Elston T, Rodan I, Flemming D, et al. 2001. Report of the American Association of Feline Practitioners (AAFP) and Academy of Feline Medicine (AFM) Advisory Panel on Feline Vaccines. Part 1. Compend Contin Educ Pract Vet 23:116-126.
  223. Elston T, Rodan I, Fleming D, et al. 2001. Report of the American Association of Feline Practitioners (AAFP) and Academy of Feline Medicine (AFM) Advisory Panel on Feline Vaccines. Part II. Feline vaccine liability and management. Compend Contin Educ Pract Vet 23:116-126.
  224. Engelman RW, Good RA, Day NK. 1987. Clearance of retroviremia and regression of malignancy in cats with leukemia-lymphoma during treatment with staphylococcal protein A. Cancer Detect Prev 10:435-444.
  225. England GCW, Allen WE. 1991. The lack of effect of parvovirus vaccination on the seminal characteristics of dogs. Vet Rec 128:611-612.
  226. Englund JA. 2007. The influence of maternal immunization on infant immune responses. J Comp Pathol 137:S16-S19.
  227. Erles K, Toomey C, Brooks HW, et al. 2003. Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease. Virology 310:216-223.
  228. Esplin DG, Bigelow M, McGill LD, et al. 1999. Fibrosarcoma at the site of a lufenuron injection in a cat. Vet Cancer Soc Newslett 23:8-9.
  229. Esplin DG, Campbell R. 1995. Widespread metastasis of a fibrosarcoma associated with a vaccination site in a cat. Feline Pract 23:13-16.
  230. Esplin DG, McGill LD, Meininger AC, et al. 1993. Postvaccination sarcomas in cats. J Am Vet Med Assoc 202:1245-1247.
  231. European Unions. 2006. The Pets Travel Scheme (PETS). Fact sheet 1. http://www.shipyourpet.com/pdf/factsheet1.pdf. Accessed 3/13/11.
  232. Evermann JF. 2008. Accidental introduction of viruses into companion animals by commercial vaccines. Vet Clin Small Anim 38:919-929.
  233. Evermann JF, McKeirnan AJ, Wilbur LA, et al. 1994. Canine fatalities associated with use of a modified live vaccine administered during late stages of pregnancy. J Vet Diagn Invest 6:353-357.
  234. Faber M, Li J, Kean RB, et al. 2009. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc Natl Acad Sci USA 106:11300-11305.
  235. Fankhauser R, Freudiger V, Vandevelde M, et al. 1973. Purkinje cell atrophy following measles virus vaccination in dogs. Schweiz Arch Neurol Neurochir Psychiatr 112:353-356.
  236. Fehr D, Holznagel E, Bolla S, et al. 1997. Placebo-controlled evaluation of a modified live virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions. Vaccine 15:1101-1109.
  237. Feng S, Kasten RW, Werner JA, et al. 2009. Immunogenicity of Bartonella henselae P26 in cats. Vet Immunol Immunopathol 132:251-256.
  238. Fenwick B. 1999. Reliable prevention of kennel cough. North Am Vet Conf, January 9–13, OrLando, FL.
  239. Fischer L, Troel JP, Pardo-David C, et al. 2002. Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge. Vaccine 20:3485-3497.
  240. Fischer SM, Quest CM, Dubovi EJ, et al. 2007. Response of feral cats to vaccination at the time of neutering. J Am Vet Med Assoc 230:52-58.
  241. FitzGerald J. 2010. Canine vaccination schedules. Vet Rec 166:280-281.
  242. Flynn JN, Cannon CA, Neil JC, et al. 1997. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection. J Virol 71:7586-7592.
  243. Flynn JN, Hosie MJ, Rigby MA, et al. 2000. Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination. Vaccine 18:1118-1132.
  244. Foale RD, Herrtage ME, Day MJ. 2003. Retrospective study of 25 young Weimaraners with low serum immunoglobulin concentrations and inflammatory disease. Vet Rec 153:553-558.
  245. Fogleman RW, Chapdelaine JM, Carpenter RH, et al. 1992. Toxicologic evaluation of injectable acemannan in the mouse, rat and dog. Vet Hum Toxicol 34:201-205.
  246. Foley J, Rosen DK. 1999. Risks and benefits of modified-live versus killed virus vaccines in multiple cat situations. J Am Vet Med Assoc 214:620-622.
  247. Foley JE, Orgad U, Hirsh DC, et al. 1999. Outbreak of fatal salmonellosis in cats following use of a high-titer modified-live panleukopenia virus vaccine. J Am Vet Med Assoc 214:67-70.
  248. Ford RB. 2002. How much vaccination is too much? Vet Forum Jan:35-41.
  249. Ford RB. 1998. Vaccines and vaccinations: issues for the 21st century. Suppl Compend Contin Educ Pract Vet 20:19-24.
  250. Fox J. 1997. Renewed signs immunomodulators help to overcome infections. ASM News 63:656-657.
  251. Fox JL. 2001. Vaccine tales wag dogs, mice, and men and women and children. ASM News 67:345-346.
  252. Fox LM, Bruederle JB. 1996. Nearly foolproof parvovirus treatments. Vet Forum 13(Apr):36-38.
  253. Francis AH, Martin LG, Haldorson GJ, et al. 2007. Adverse reactions suggestive of type III hypersensitivity in six health dogs given human albumin. J Am Vet Med Assoc 230:873-879.
  254. Franka R, Wu X, Jackson FR, et al. 2009. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines. Vaccine 27:7149-7155.
  255. Freitag KA, Saker KE, Thomas E, et al. 2000. Acute starvation and subsequent refeeding affect lymphocyte subsets and proliferation in cats. J Nutr 130:2444-2449.
  256. Frick OL, Brooks DL. 1983. Immunoglobulin E antibodies to pollens augmented in dogs by virus vaccines. Am J Vet Res 44:440-445.
  257. Frymus T, Addie D, Belak S, et al. 2009. Feline rabies. J Feline Med Surg 11:585-593.
  258. Fukumoto S, Tamaki Y, Igarashi I, et al. 2009. Immunogenicity and growth inhibitory efficacy of the prime-boost immunization regime with DNA followed by recombinant vaccinia virus carrying the P29 gene of Babesia gibsoni in dogs. Exp Parasitol 123:296-301.
  259. Fulton R, Gasper PW, Ogilvie GK, et al. 1991. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats. Exp Hematol 19:759-767.
  260. Gagnon AC. 2000. Drug injection-associated fibrosarcoma in a cat. Feline Pract 28:18-21.
  261. Galazka A. 2000. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 181(Suppl 1):S2-S9.
  262. Galil K, Fair E, Mountcastle N, et al. 2002. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 186:102-105.
  263. Gallin JI. 2001. Phagocyte function and dysfunction: from descriptive biology to molecular defects and cytokine therapy, article #34. Pfizer/IDCP Discovery Series.
  264. Gallin JI, Farber JM, Holland SM, et al. 1995. Interferon-γ in the management of infectious diseases. Ann Intern Med 123:216-224.
  265. Gallin JI, Farber JM, Holland SM, et al. 1995. Interferon-γ in the management of infectious diseases. Ann Intern Med 123:216-224.
  266. 264a.Gamiz C, Martella V, Ulloa R, et al. 2011. Identification of a new genotype of canine distemper virus circulating in America. Vet Res Commun 35:381-390.
  267. Gamoh K, Shimazaki Y, Makie H, et al. 2003. The pathogenicity of canine parvovirus type-2b, FP84 strain isolated from a domestic cat, in domestic cats. J Vet Med Sci 65:1027-1029.
  268. Gamoh K, Shimazaki Y, Senda M, et al. 2003. Antigenic type distribution of parvovirus isolated from domestic cats in Japan. Vet Rec 153:751.
  269. Gans HA, Arvin AM, Galinus J, et al. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280:527-532.
  270. Gaskell RM. 1975. Studies on feline viral rhinotracheitis virus with particular reference to the carrier state. Doctoral dissertation. University of Bristol, Bristol, UK.
  271. Gaskell RM. 1989. Vaccination of the young kitten. J Small Anim Pract 30:618-624.
  272. Gaskell RM, Dawson S, Jacobs AAC, et al. 1998. The role of Bordetella in feline respiratory disease. Companion Anim Tech Rep 14:2-4.
  273. Gaskell RM, Dawson S, Radford AD. 2006. Duration of immunity (DOI)—the regulatory issues. Vet Microbiol 117:80-85.
  274. Gaskell RM, Gettinby G, Graham SJ, et al. 2002. Veterinary Products Committee Working Group report on feline and canine vaccination. Vet Rec 150:126-134.
  275. Gehring R, Eggars B. 2001. Suspected post-vaccinal acute polyradiculoneuritis in a puppy. Tydskr S Afr Vet Ver 72:96.
  276. Gerber JD, Brown AL. 1974. Effect of development and aging on the immune response of canine lymphocytes to phytohemagglutinin. Infect Immun 10:695-699.
  277. Gerber JD, Ingersoll JD, Gast AM, et al. 1990. Protection against feline infectious peritonitis by intranasal inoculation of a temperature-sensitive FIPV vaccine. Vaccine 8:536-542.
  278. Gerdts V, Mutwiri GK, Tikoo SK, et al. 2006. Mucosal delivery of vaccines in domestic animals. Vet Res 37:487-510.
  279. German AC, Helps CR, Harbour DA. 2004. FIP: a novel approach to vaccination. J Feline Med Surg 6:119-124.
  280. Gilbert JH, Pedersen NC, Nunberg JH. 1987. Feline leukemia virus envelope protein expression encoded by a recombinant vaccinia virus: apparent lack of immunogenicity in vaccinated animals. Virus Res 7:49-67.
  281. Gill M, Shrivas J, Morozov I, et al. 2004. Three-year duration of immunity for canine distemper, adenovirus, and parvovirus after vaccination with a multivalent canine vaccine. Int J Appl Res 2:227-235.
  282. Gillespie JH, Baker JA, Burgher J, et al. 1958. The immune response of dogs to distemper virus. Cornell Vet 48:103-126.
  283. Gisel JJ, Brumble LM, Johnson MM. 2010. Bordetella bronchiseptica pneumonia in a kidney-pancreas transplant patient after exposure to recently vaccinated dogs. Transpl Infect Dis 12:73-76.
  284. Glardon O, Stockli R. 1985. Staupeepidemie in der Schweiz: Epidemiologie und Impfanamnese. Schweiz Arch Tierheilkd 127:706-717.
  285. Gleich SE, Krieger S, Hartmann K. 2009. Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany. J Feline Med Surg 11:985-992.
  286. Glenn GM, Scharton-Kersten T, Vassell R, et al. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161:3211-3214.
  287. Gobar GM, Kass PH. 2002. World Wide Web-based survey of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. J Am Vet Med Assoc 220:1477-1482.
  288. Godsall SA, Clegg SR, Stavisky JH, et al. 2010. Epidemiology of canine parvovirus and coronavirus in dogs presented with severe diarrhoea to PDSA PetAid hospitals. Vet Rec 167:196-201.
  289. Goldberg JD, Kamboj M, Ford R, et al. 2009. Bone Marrow Transplant 44:381-382.
  290. Goldberg JD, Kamboj M, Ford R, et al. 2009. “Kennel Cough” in a patient following allogeneic hematopoietic stem cell transplant [Letter to the editor]. Bone Marrow Transplant 44:381-382.
  291. Goller KV, Fyumagwa RD, Nikolin V. 2010. Fatal canine distemper infection in a pack of African wild dogs in the Serengeti ecosystem, Tanzania. Vetmic 146:245-252.
  292. Gopinathan L, Kirimanjeswara GS, Wolfe DN, et al. 2007. Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. Microbes Infect 9:442-448.
  293. Gordon PJ. 2002. Control of leptospirosis by vaccination. Vet Rec 150:420.
  294. Gore T, Headley M, Laris R. 2005. Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours. Vet Rec 156:482-483.
  295. Gore TC, Lakshmanan N, Duncan KL, et al. 2005. Three-year duration of immunity in dogs following vaccination against canine adenovirus type-1, canine parvovirus, and canine distemper virus. Vet Ther 6:5-14.
  296. Gore TC, Lakshmanan N, Williams JR, et al. 2006. Three-year duration of immunity in cats following vaccination against feline rhinotracheitis virus, feline calicivirus, and feline panleukopenia virus. Vet Ther 7:213-222.
  297. Goriely S, Goldman M. 2007. From tolerance to autoimmunity: is there a risk in early life vaccination? J Comp Pathol 137:S57-S61.
  298. Gray AK. 1998. Cat and dog vaccination: results from the suspected adverse reaction surveillance scheme. Vet Rec 455.
  299. Greeley EH, Ballam JM, Harrison JM, et al. 2001. The influence of age and gender on the immune system: a longitudinal study in Labrador retriever dogs. Vet Immunol Immunopathol 82:57-71.
  300. Greenacre CB. 2003. Incidence of adverse events in ferrets vaccinated with distemper or rabies vaccine: 143 cases (1995–2001). J Am Vet Med Assoc 223:663-665.
  301. Greene CE. 1984. Immunoprophylaxis and immunotherapy, pp 321-355. In Greene CE (ed): Clinical microbiology and infectious diseases of the dog and cat. WB Saunders, Philadelphia.
  302. Greene CE. 1990. Immunoprophylaxis and immunotherapy, pp 21-63. In Greene CE (ed): Infectious diseases of the dog and cat, ed 1. WB Saunders, Philadelphia.
  303. Greene CE. 1998. Immunoprophylaxis and immunotherapy, pp 717-750. In Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  304. Greene CE. 2003. Unpublished observations. University of Georgia, Athens, GA.
  305. Greene CE. 2010. Unpublished observations. University of Georgia, Athens, GA.
  306. Greene CE, Schultz RD. 2006. Immunoprophylaxis, pp 1069-1119. In Greene CE (ed): Infectious diseases of the dog and cat, ed 3. St Louis, Elsevier.
  307. Greene RT, Hirsch DA, Rottman PL. 1991. Interlaboratory comparison of titers of antibody to Borrelia burgdorferi and evaluation of a commercial assay using canine sera. J Clin Microbiol 29:16-20.
  308. Griot C, Moser C, Cherpillod P, et al. 2004. Early DNA vaccination of puppies against canine distemper in the presence of maternally derived immunity. Vaccine 22:650-654.
  309. Grosenbaugh DA, Leard T, Pardo MC, et al. 2004. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously. Vet Ther 5:258-262.
  310. Gruffydd-Jones T, Addie D, Belak S, et al. 2009. Chlamydophila felis infection. ABCD guidelines on prevention and management. J Feline Med Surg 11:605-609.
  311. Gueguen S, Martin V, Bonnet L, et al. 2000. Safety and efficacy of a recombinant FeLV vaccine combined with a live feline rhinotracheitis, calicivirus and panleukopenia vaccine. Vet Rec 146:380-381.
  312. Guglielmino R, Miniscalco B, Iussich S, et al. 2004. Feline vaccine-associated sarcomas: cytological results and histological correlations. In ESCVP 6th Annual Meeting, Olsztyn, Poland, Sept 15-17 and ESVCP Special Program, Barcelona, Spain, Sept 9-11.
  313. Guglielmino R, Miniscalco B, Martano M, et al. 2005. Flow cytometric DNA ploidy and cell-cycle in feline vaccine-associated sarcoma. Oral platform presentations, ESVCP 7th Annual Meeting, Utrecht, The Netherlands, June 21-24.
  314. Guilot AL, Cariou C, Krogmann V, et al. 2008. Compatibility between a rabies vaccine and a combined vaccine against feline rhinotracheitis, FCV, FPLV and FeLV, and Chlamydophila felis. Vet Rec 162:690-692.
  315. Gumley N. 1998. CVMA position statement on vaccine protocols ill considered: the CVMA national issues committee responds. Can Vet J 39:477-478.
  316. Gumley N. 1999. Update on revaccination protocols. Can Vet J 40:323-324.
  317. Gumley N. 2000. Revaccination guidelines revisited. Can Vet J 41:26-27.
  318. Guo Y, German TC, Schultz RD. 2003. Expression of canine parvovirus-2 (CPV-2) VP1, 2 in plants: the potential of developing an oral vaccine, abstract no 57. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13-18, Guelph, Ontario, Canada.
  319. Ricklin Gutzwiller ME, Reist M, Peel J, et al. 2007. Intradermal injection of heat-killed Mycobacterium vaccae in dogs with atopic dermatitis: a multicentre pilot study. Vet Dermatol 18:87-93.
  320. Habacher G, Gruffydd-Jones T, Murray J. 2010. Use of a web-based questionnaire to explore cat owners’ attitudes towards vaccination in cats. Vet Rec 167:122-127
  321. Haase C, Larson L, Peek J, et al. Feral cats in Dane county Wisconsin are found to have an exceptionally low prevalence of most infectious diseases. International Veterinary Vaccine Abstract 60. In Proceedings 3rd International Veterinary Vaccine DC, Guelph, Ontario. July 13-18.
  322. Haffer KN, Koertje WD, Deer JT, et al. 1990. Evaluation of immunosuppressive effect and efficacy of an improved-potency feline leukemia virus vaccine. Vaccine 8:12-16.
  323. Haijema BJ, Volders H, Rottier PJ. 2004. Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis. J Virol 78:3863-3871.
  324. Hammami S, Schumacher CL, Cliquet F, et al. 1999. Safety evaluation of the SAG2 rabies virus mutant in Tunisian dogs and several non-target species. Vet Res 30:353-362.
  325. Hammond SA, Tsonis C, Sellens K, et al. 2000. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 43:45-55.
  326. Hampel V, Schwarz B, Kempf C, et al. 2007. Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-ω. J Vet Intern Med 21:1340-1346.
  327. Hanlon CA, Niezgoda M, Rupprecht CE. 2002. Postexposure prophylaxis for prevention of rabies in dogs. Am J Vet Res 63:1096-1100.
  328. Hanlon L, Argyle DJ. 2001. The science of DNA vaccination. Infect Dis Rev 3:2-12.
  329. Harbour DA, Gunn-Moore DA, Gruffydd-Jones TJ, et al. 2002. Protection against oronasal challenge with virulent feline leukaemia virus lasts for at least 12 months following a primary course of immunization with Leukocell 2 vaccine. Vaccine 20:2866-2872.
  330. Harder TC, Kuczka A, Dubberke M, et al. 1991. Ein Ausbruch von Hundestaupe in einem Tierheim mit vakzinierter Hundepopulation. Kleintierpraxis 36:305-314.
  331. Harley R, Catanese B, Helps C. 2010. Polymorphic membrane proteins 1 and 7 from Chlamydophila felis are significant immunodominant proteins. Vet Microbiol 144:415-421.
  332. Harris C, Pierce K, King G, et al. 1991. Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms. Mol Biother 3:207-213.
  333. Harrus S, Waner T, Aizenberg I, et al. 2002. Development of hypertrophic osteodystrophy and antibody response in a litter of vaccinated Weimaraner puppies. J Small Anim Pract 43:27-31.
  334. Heaton PR, Blount DG, Devlin P, et al. 2002. Assessing age-related changes in peripheral blood leukocyte phenotypes in Labrador retriever dogs using flow cytometry. J Nutr 132:1655S-1657S.
  335. Hebben M, Duquesne V, Cronier J, et al. 2004. Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy. J Feline Med Surg 6:111-118.
  336. Hebert D, Eschner A. 2010. Seroprevalence of Borrelia burgdorferi–specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic. Vet Ther 11:E1-E9.
  337. Hedrick PW, Lee RN, Buchanan C. 2003. Canine parvovirus enteritis, canine distemper, and major histocompatibility complex genetic variation in Mexican wolves. J Wildl Dis 39:909-913.
  338. Helms TD, Bain MJ. 2009. Evaluation of owner attachment to dogs on the basis of whether owners are legally considered guardians of their pets. J Am Vet Med Assoc 234:896-900.
  339. Hendrick MJ. 1998. Feline vaccine-associated sarcomas: current studies on pathogenesis. J Am Vet Med Assoc 213:1425-1426.
  340. Hendrick MJ. 1998. Historical review and current knowledge of risk factors involved in feline vaccine-associated sarcomas. J Am Vet Med Assoc 213:1422-1423.
  341. Hendrick MJ. 1999. Feline vaccine-associated sarcomas. Cancer Invest 17:273-277.
  342. Hendrick MJ, Brooks JJ. 1994. Postvaccinal sarcomas in the cat: histology and immunochemistry. Vet Pathol 34:126-129.
  343. Hendrick MJ, Dunagan CA. 1991. Focal necrotizing granulomatous panniculitis associated with subcutaneous injection of rabies vaccine in cats and dogs: 10 cases (1988–1989). J Am Vet Med Assoc 198:304-305.
  344. Hendrick MJ, Goldschmidt MH. 1991. Do injection site reactions induce fibrosarcoma in cats (letter). J Am Vet Med Assoc 199:968.
  345. Hendrick MJ, Goldschmidt MH, Shofer FS, et al. 1992. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Res 52:5391-5394.
  346. Hendrick MJ, Shofer FS, Goldschmidt MH, et al. 1994. Comparison of fibrosarcomas that developed at vaccination sites and at nonvaccination sites in cats: 239 cases (1991–1992). J Am Vet Med Assoc 205:1425-1429.
  347. Hendrick MJ, Sorenmo KU, Hendrick MJ, et al. 2000. Prognosis for vaccine-associated sarcoma after excision. J Am Vet Med Assoc 216:58-61.
  348. Henke D, Vandevelde M, Oevermann A. 2009. Polyganglioradiculoneuritis in a young cat: clinical and histopathological findings. J Small Anim Pract 50:246-250.
  349. Henry CJ, McCaw DL, Brock KV, et al. 2001. Association between cancer chemotherapy and canine distemper virus, canine parvovirus, and rabies virus antibody titers in tumor-bearing dogs. J Am Vet Med Assoc 219:1238-1241.
  350. Hershey AE, Dubielzig RR, Helfand SC. 2000. P53 expression in feline vaccinal sarcomas. In Proceedings of the 18th Annual Meeting of the American College of Veterinary Internal Medicine, Seattle.
  351. Hershey AE, Dubielzig RR, Padilla ML, Helfand SC. 2005. Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosis. Vet Pathol 42:805-811.
  352. Hershey AE, Sorenmo KU, Hendrick MJ, et al. 2000. Prognosis for presumed feline vaccine-associated sarcoma after excision: 61 cases (1986–1996). J Am Vet Med Assoc 216:58-61.
  353. Hill RJ. 2006. Duration of immunity (DOI) and booster vaccination-dealing with the issue at practice level in the UK. Vet Microbiol 117:93-97.
  354. Hilsenroth R. 1998. Molecular analysis of feline vaccine-induced sarcomas. Feline Pract 26:24.
  355. Hines DL, Cutting JA, Dietrich D, et al. 1991. Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection. J Am Vet Med Assoc 199:1428-1430.
  356. Hird DW, Ruble RP, Reagor SG, et al. 1992. Morbidity and mortality in pups from pet stores and private sources: 968 cases (1987–1988). J Am Vet Med Assoc 201:471-474.
  357. Hoffmann-Lehmann R, Holznagel E, Aubert A, et al. 1995. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection. Vet Immunol Immunopathol 46:127-137.
  358. HogenEsch H, Azcona-Olivera JI, Scott-Moncrieff JC, et al. 1999. Vaccine-induced autoimmunity in the dog. Adv Vet Med 41:733-747.
  359. HogenEsch H, Dunham AD, Scott-Montcrief JC, et al. 2002. Effect of vaccination on serum concentrations of total and antigen-specific immunoglobulin E in dogs. Am J Vet Res 63:611-616.
  360. HogenEsch H, Thompson S. 2010. Effect of ageing on the immuno response of dogs to vaccines. J Comp Pathol 142(Suppl 1):S74-S77.
  361. HogenEsch H, Thompson S, Dunham A, et al. 2004. Effect of age on immune parameters and the immune response of dogs to vaccines: a cross-sectional study. Vet Immunol Immunopathol 97:77-85.
  362. Hoover EA, Mullins JI, Chu HJ, et al. 1995. Development and testing of an inactivated feline leukemia virus vaccine. Semin Vet Med Surg 10:238-243.
  363. Hoover EA, Mullins JI, Chu HJ, et al. 1996. Efficacy of an inactivated feline leukemia virus vaccine. AIDS Res Hum Retroviruses 12:379-383.
  364. Horber D, Mayr B. 1991. Paramunisierung FeLV-positiver Katzen mit PIND-AVI. Tierarztl Prax 19:311-314.
  365. Horvath C, Neuber A, Litschauer B. 2007. Pemphigus foliaceus-like drug reaction in a 3-month-old crossbreed dog treated for juvenile cellulitis. Vet Dermatol 18:353-359.
  366. Horzinek MC. 2006. Concluding remarks. Vet Microbiol 117:98-101.
  367. Horzinek MC. 2006. Vaccine use and disease prevalence in dogs and cats. Vet Microbiol 117:2-8.
  368. Horzinek MC. 2010. Vaccination protocols for companion animals: the veterinarian's perspective. J Comp Pathol 142(Suppl 1):S129-S132.
  369. Horzinek MC, Thiry E. 2009. Vaccines and vaccination: the principles and the polemics. J Feline Med Surg 11:530-537.
  370. Hosie MJ, Addie D, Belak S, et al. 2009. Feline immunodeficiency. ABCD guidelines on prevention and management. J Feline Med Surg 11:575-584.
  371. Hosie MJ, Beatty JA. 2007. Letter to the editor. Aust Vet J 85:303.
  372. Hosie MJ, Beatty JA. 2007. Vaccine protection against feline immunodeficiency virus: setting the challenge. Aust Vet J 85(1&2):5-12.
  373. Hosie MJ, Dunsford T, Klein D, et al. 2000. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol 74:9403-9411.
  374. Hosie MJ, Jarret O. 1999. Analysis of the protective immunity induced by feline immunodeficiency virus vaccination. Adv Vet Med 41:325-332.
  375. Hoskins JD. 1997. Update on canine parvoviral enteritis. Vet Med 92:694-709.
  376. Hoskins JD. 1997. Performance of a new generation canine parvovirus vaccine in Rottweiler puppies. Canine Pract 22:29-31.
  377. Hoskins JD. 1997. What role does Bordetella bronchiseptica infection play in pneumonia of cats, young kittens? DVM newsmagazine
  378. Hoskins JD. 2000. Vaccine reaction or toxic shock? Vet Forum Jul:36.
  379. Houston DM, Ribble CS, Head LL. 1996. Risk factors associated with parvovirus enteritis in dogs: 283 cases (1982–1991). J Am Vet Med Assoc 208:542-546.
  380. Hoyumpa VA, Rodan I, Brown M, et al. 2010. AAFP-AAHA: feline life stage guidelines. J Feline Med Surg 12:43-54.
  381. Huang C, Conlee D, Gill M, et al. 2010. Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge. J Feline Med Surg 12:451-457.
  382. Huang C, Conlee D, Loop J, et al. 2004. Efficacy and safety of a feline immunodeficiency virus vaccine. Anim Health Res Rev 5: 295-300.
  383. Huang C, Hess J, Gill M, et al. 2010. A dual-strain feline calicivirus vaccine stimulates broader cross-neutralization antibodies than a single-strain vaccine and lessens clinical signs in vaccinated cats when challenged with a homologous feline calicivirus strain associated with virulent systemic disease. J Feline Med Surg 12:129-137.
  384. Huisman W, Karlas JA, Siebelink KH, et al. 1998. Feline immunodeficiency virus subunit vaccines that induce virus neutralizing antibodies but no protection against challenge infection. Vaccine 16:181-187.
  385. Hurley KE, Pesavento PA, Pedersen NC, et al. 2004. An outbreak of virulent systemic feline calicivirus disease. J Am Vet Med Assoc 224:241-249.
  386. Hustead DR, Carpenter T, Sawyer DC, et al. 1999. Vaccination issues of concern to practitioners. J Am Vet Med Assoc 214:1000-1002.
  387. Iemura R, Tsukatani R, Micallef MJ, et al. 2009. Simultaneous analysis of the nasal shedding kinetics of field and vaccine strains of Bordetella bronchiseptica. Vet Rec 165:747-751.
  388. Iglauer F, Gartner K, Morstedt R. 1989. Maternal protection against feline respiratory disease by means of booster vaccines during pregnancy. A retrospective clinical study. Kleintierpraxis 34:235-242.
  389. Iida H, Fukuda S, Kawashima N, et al. 1990. Effect of maternally derived antibody levels on antibody responses to canine parvovirus, canine distemper virus and infectious canine hepatitis virus after vaccinations in beagle puppies. Exp Anim 39:9-19.
  390. Ikeda Y, Mochizuki M, Naito R, et al. 2000. Predominance of canine parvovirus (CPV) in unvaccinated cat populations and emergence of new antigenic types of CPVs in cats. Virology 278:13-19.
  391. Ishibashi K, Maede Y, Ohsugi T, et al. 1983. Serotherapy for dogs infected with canine parvovirus. Jpn J Vet Sci 45:59-66.
  392. Jacobs AAC, Bergman JGHE, Theelen RPH, et al. 2007. Compatibility of a bivalent modified-live vaccine against Bordetella bronchiseptica and Cpiv, and a trivalent modified-live vaccine against CPV, CDV and CAV-2. Vet Rec 160:41-45.
  393. 390a. Jacobs AAC, Theelen RPH, Jaspers R, et al. 2005. Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. Vet Rec 157:19-23.
  394. Jacobs LD, Beck RW, Simon JH, et al. 2000. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904.
  395. Jarrett O, Ganiere JP. 1996. Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine. Vet Rec 138:7-11.
  396. Jarrett O, Russell PH, Stewart MF. 1977. Protection of kittens from feline leukemia virus infection by maternally derived antibody. Vet Rec 101:304-305.
  397. Jas D, Aeberle C, Lacombe V, et al. 2009. Onset of immunity in kittens after vaccination with a non-adjuvanted vaccine against feline panleucopenia, feline calicivirus and feline herpesvirus. Vet J 182:86-93.
  398. Jelínek F. 2003. Postinflammatory sarcoma in cats. Exp Toxicol Pathol 55:167-172.
  399. Jennings M, Morton DB, Charton E, et al. 2010. Application of the three Rs to challenge assays used in vaccine testing: tenth report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. Biologicals 38:684-695.
  400. Jensen TH, Nielsen L, Aasted B, et al. 2009. Early life DNA vaccination with the H gene of canine distemper virus induces robust protection against distemper. Vaccine 27:5178-5183.
  401. Jessup DA, Murray MJ, Casper DR, et al. 2009. Canine distemper vaccination is a safe and useful preventive procedure for southern sea otters (Enhydra lutra nereis). J Zoo Wildl Med 40:705-710.
  402. Jiang W, Baker HJ, Swango LJ, et al. 1998. Nucleic acid immunization protects dogs against challenge with virulent canine parvovirus. Vaccine 16:601-607.
  403. Jirjis FF, Davis T, Lane J, et al. 2010. Protection against feline leukemia virus challenge for at least 2 years after vaccination with an inactivated feline leukemia virus vaccine. Vet Ther 11:E1-E6.
  404. Jirjis FF, Deshpande MS, Tubbs AL, et al. 2010. Transmission of canine influenza virus (H3N8) among susceptible dogs. Vet Microbiol 4804:1-7.
  405. Johnson R, Glickman LT, Emerick TJ, et al. 1995. Canine distemper in pet dogs: I. Surveillance in Indiana during a suspected outbreak. J Am Anim Hosp Assoc 31:223-229.
  406. Johnson RP. 1980. Immunity to feline calicivirus in kittens. Doctoral dissertation. University of Guelph, Guelph, Ontario, Canada.
  407. Johnson RP, Povey RC. 1983. Transfer and decline of maternal antibody to feline calicivirus. Can Vet J 24:6-9.
  408. Johnston WB, Walden MB. 1996. Results of a national survey of rabies control procedures. J Am Vet Med Assoc 208:1667-1672.
  409. Jones PD, Kitchell BE. 2002. Vaccine-associated sarcomas in cats: applying the latest research to practice. Vet Med 97:34-44.
  410. Jönsdottir I. 2007. Maturation of mucosal immune responses and influence of maternal antibodies. J Comp Pathol 137:S20-S26.
  411. Junge RE, Bauman K, King M, et al. 2007. A serologic assessment of exposure to viral pathogens and Leptospira in an urban raccoon (Procyon lotor) population inhabiting a large zoological park. J Zoo Wildl Med 38:18-26.
  412. Kahler S. 1993. Collective effort needed to unlock factors related to feline injection site sarcomas. J Am Vet Med Assoc 202:1551-1554.
  413. Kahlon JB, Kemp MC, Yawei N, et al. 1991. In vitro evaluation of the synergistic antiviral effects of acemannan in combination with azidothymidine and acyclovir. Mol Biother 3:214-223.
  414. Kanasugi H, Hasegawa T, Yamamoto T, et al. 1996. Optimal dose of enterococcal preparation (FK-23) supplemented personally for stimulation of leukocyte reconstitution in dogs treated with cyclophosphamide. J Vet Med Sci 58:563-565.
  415. Kanellos T, Sutton DJ, Salisbury CF, et al. 2008. Combined administration in a single injection of a feline multivalent modified live vaccine against FHV, FCH, and FPLV together with a recombinant FeLV vaccine is both safe and efficacious for all four major feline viral pathogens. J Feline Med Surg 10:346-354.
  416. Kapil S, Allison RW, Johnson L, et al. 2008. Canine distemper virus strains circulating among North American dogs. Clin Vaccine Immunol 15:707-712.
  417. Kapil S, Yueary T, Johnson B. 2008. Diagnostic investigation of emerging viruses of companion animals. Vet Clin Small Anim 38:755-774.
  418. Kaplan E. 1998. Proof required of effectiveness of proposed new feline vaccination protocols. Can Vet J 39:607.
  419. Karlas JA, Siebelink KH, Peer MA, et al. 1998. Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells. Vet Immunol Immunopathol 65:353-365.
  420. Karlas JA, Siebelink KH, Peer MA, et al. 1999. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 80:761-765.
  421. Kass PH, Barnes WG, Spangler WL, et al. 1993. Epidemiologic evidence of a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. J Am Vet Med Assoc 203:396-405.
  422. Kass PH, Spangler WL, Hendrick MJ, et al. 2003. Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats. J Am Vet Med Assoc 223:1283-1292.
  423. Katayama R, Huelsmeyer MK, Marr AK, et al. 2004. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 54:25-33.
  424. Katz SL. 2000. Editorial response: a tale of two vaccines. Clin Infect Dis 31:671-672.
  425. Kearns RJ, Marshall CA, Adams SM, et al. 1999. Effect of age, breed and dietary omega-6 (n-6) and omega-3 (n-3) fatty acid ratio on immune function, eicosanoid production and lipid peroxidation in young and aged dogs. Vet Immunol Immunopathol 69:165-183.
  426. Keil DJ, Fenwick B. 1999. Evaluation of canine Bordetella bronchiseptica isolates using randomly amplified polymorphic DNA fingerprinting and ribotyping. Vet Microbiol 66:41-51.
  427. Keil D, Fenwick B. 1999. Pertactin and filamentous hemagglutinin as subunit vaccine antigens to prevent canine bordetellosis, p 15. In Proceedings of the Meeting on Canine Infectious Diseases: From Clinics to Molecular Pathogenesis, Aug 12-14, Ithaca, NY.
  428. Keil DJ, Fenwick B. 1998. Role of Bordetella bronchiseptica in infectious tracheobronchitis in dogs. J Am Vet Med Assoc 212:200-207.
  429. Kelly DF, Miller JL. 2010. Reporting of injection-site sarcomas in cats. Vet Rec 167:389
  430. Kelly GE, Webster AC. 1980. The effect of surgery in dogs on the response to concomitant distemper vaccination. Aust Vet J 56:556-557.
  431. Kennedy LJ, Lunt M, Barnes A, et al. 2007. Factors influencing the antibody response of dogs vaccinated against rabies. Vaccine 25:8500-8507.
  432. Kent EM. 1993. Use of an immunostimulant as an aid in treatment and management of fibrosarcoma in three cats. Feline Pract 21:13-17
  433. Khawplod P, Tantawichien T, Wilde H, et al. 2002. Use of rabies vaccines after reconstitution and storage. Clin Infect Dis 34:404-406.
  434. Khoo C, Cunnick J, Friesen K, et al. 2005. The role of supplementary dietary antioxidants on immune response in puppies. Vet Ther 6:43-56.
  435. Kidney BA, Ellis JA, Haines DM, et al. 2000. Evaluation of formalin-fixed paraffin-embedded tissues obtained from vaccine site-associated sarcomas of cats for DNA of feline immunodeficiency virus. Am J Vet Res 61:1037-1041.
  436. Kidney BA, Haines DM, Ellis JA, et al. 2001. Evaluation of formalin-fixed paraffin-embedded tissues from vaccine site-associated sarcomas of cats for polyomavirus DNA and antigen. Am J Vet Res 62:828-832.
  437. Kidney BA, Haines DM, Ellis JA, et al. 2001. Evaluation of formalin-fixed paraffin-embedded tissues from vaccine site-associated sarcomas of cats for papillomavirus DNA and antigen. Am J Vet Res 62:833-839.
  438. Kiel DJ, Fenwick B. 1999. Evaluation of canine Bordetella bronchiseptica isolates using randomly amplified polymorphic DNA fingerprinting and ribotyping. Vet Microbiol 66:41-51.
  439. Kim DK, Kim JJ, Kim JH, et al. 2001. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine 19:1274-1283.
  440. King GK, Yates KM, Greenlee PG, et al. 1995. The effect of acemannan immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. J Am Anim Hosp Assoc 31:439-447.
  441. Kirpensteijn J. 2006. Feline injection site-associated sarcoma: is it a reason to critically evaluate our vaccination policies? Vet Microbiol 117:59-65.
  442. Kiss I, Poland AM, Pedersen NC. 2004. Disease outcome and cytokine responses in cats immunized with an avirulent feline infectious peritonitis virus FIPV-UCD8. J Feline Med Surg 6:89-97.
  443. Klaasen HL, Molkenboer MJ, Vrijenhoek MP, et al. 2003. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. Vet Microbiol 95:121-132.
  444. Klingborg DJ. 2003. Dr. Klingborg responds. J Am Vet Med Assoc 222:150-151.
  445. Klingborg DJ. 2004. Rabies vaccination in cats: a professional dilemma. Vet Forum 21:22-24.
  446. Klingborg DJ, Hustead DR, Curry-Galvin EA. 2002. AVMA Council on biologic and therapeutic agents’ report on cat and dog vaccinations. J Am Vet Med Assoc 21:1401-1407.
  447. Klotins KC, Martin SW, Kruth S, et al. 2003. Vaccination as a risk factor for immune mediated anemia in dogs: a multi-centre case-control study, abstract no 31. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13-18, Guelph, Ontario, Canada.
  448. Kohn B, Garner M, Lubke S, et al. 2003. Polyarthritis following vaccination in four dogs. Vet Comp Orthop Trauma 16:6-10.
  449. Koizumi N, Wantanabe H. 2004. Leptospiral immunoglobulin-like proteins elicit protective immunity. Vaccine 22:1545-1552.
  450. Kojima A, Takahashi T, Kijima M, et al. 1996. Detection of mycoplasma DNA in veterinary live virus vaccines by the polymerase chain reaction. Jpn J Vet Med Sci 58:1045-1048.
  451. Kolar JR, Rude TA. 1981. Duration of immunity in cats inoculated with a commercial feline pneumonitis vaccine. Vet Med Small Anim Clin 86:1171-1173.
  452. Kolbl S, Tschabrun S, Schuller W. 1995. Examination of the humoral immune response in puppies after first immunization with different combination vaccines: 1. Distemper virus component. Kleintierpraxis 40:851-865.
  453. Kommonen E, Sihovonen L, Pekkanen K, et al. 1997. Outbreak of canine distemper in vaccinated dogs in Finland. Vet Rec 141:380-383.
  454. Kona-Boun JJ, Silim A, Troncy E. 2005. Immunologic aspects of veterinary anesthesia and analgesia. J Am Vet Med Assoc 226:355-363.
  455. Krebs JW, Wheeling JT, Childs JE. 2003. Rabies surveillance in the United States during 2002. J Am Vet Med Assoc 223:1736-1748.
  456. Kremer EJ, Boutin S, Chillon M, et al. 2000. Cine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol 74:505-512.
  457. Kruger JM, Sussman MD, Maes RK. 1996. Safety and efficacy of a recombinant feline rhinotracheitis vaccine. Virology 220:299-308.
  458. Kruse BD, Unterer S, Horlacher K, et al. 2010. Prognostic factors in cats with feline panleukopenia. J Vet Intern Med 24:1271-1276.
  459. Kruth SA, Ellis JA. 1998. Vaccination of dogs and cats: general principles and duration of immunity. Can Vet J 39:423-426.
  460. Kuehn BM. 2003. A reaction to the COBTA vaccine report. J Am Vet Med Assoc 223:751.
  461. Kulcsar G, Farsang A, Soos T. 2010. Testing for viral contaminants of veterinary vaccines in Hungary. Biologicals 38:346-349.
  462. Kusuhara H, Hohdatsu T, Seta T, et al. 2007. Serological differentiation of FIV-infected cats from dual-subtype feline immunodeficiency virus vaccine (Fel-O-Vax FIV) inoculated cats. Vet Microbiol 120:217-225.
  463. Kusi I. 1999. The debate regarding vaccination guidelines is international. J Am Vet Med Assoc 215:1091.
  464. LaFleur RL, Callister SM, Dant JC, et al. 2010. One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin. Clin Vaccine Immunol 17:870-874.
  465. Lafrado L. 1990. Biological effects of staphylococcal protein A immunotherapy in cats with induced FeLV infection. Am J Vet Res 51:482-486.
  466. Lafrado LJ. 1994. Evaluation of a feline leukemia virus vaccine in a controlled natural transmission study. J Am Vet Med Assoc 204:914-917.
  467. Lakshmanan N, Gore TC, Duncan KL, et al. 2006. Three-year rabies duration of immunity in dogs following vaccination with a core combination vaccine against canine distemper virus, canine adenovirus type-1, canine parvovirus, and rabies virus. Vet Ther 7(3):223-231.
  468. Langeveld JPM, Casal JI, Osterhaus ADME, et al. 1994. First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs. J Virol 68:4506-4513.
  469. Lappin MR, Andrews J, Simpson D, et al. 2002. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus and feline parvovirus infection in cats. J Am Vet Med Assoc 220:38-42.
  470. Lappin MR, Basaraba RJ, Jensen WA. 2006. Interstitial nephritis in cats inoculated with Crandell Rees feline kidney cell lysates. J Feline Med Surg 8:353-356.
  471. Lappin MR, Jensen WA. 2007. Panleukopenia antibody responses following a single inoculation with one of five FVRCP vaccines. Abstract 22. ACVIM forum. Seattle, WA, June 6–9. J Vet Intern Med 21:578.
  472. Lappin MR, Jensen WA, Chandrashekar R, et al. 2002. Parenteral administration of FVRCP vaccines induces antibodies against feline renal tissues, abstract no 99, p 785. In Proceedings of the 20th ACVIM Annual Forum, May 29-Jun 1, Dallas.
  473. Lappin MR, Jensen WA, Jensen TD, et al. 2005. Investigation of the induction of antibodies against Crandell-Reese feline kidney cell lysates and feline renal cell lysates after parenteral administration of vaccines against feline viral rhinotracheitis, calicivirus, and panleukopenia in cats. Am J Vet Res 66:506-511.
  474. Lappin MR, Sebring RW, Jensen WA, et al. 2004. Magnitude of Crandell Reese feline kidney cell line antibody responses of cats administered FVRCP vaccines, abstract no 198, p 856. In Proceedings of the 22nd ACVIM Annual Forum, Minneapolis.
  475. LaRosh M. 2004. Canine technical report. Three-year duration of immunity challenge studies. Fort Dodge Animal Health, Fort Dodge, IA.
  476. Larson LJ, Hageny TL, Haase CJ, et al. 2006. Effect of recombinant canine distemper vaccine on antibody titers in previously vaccinated dogs. Vet Ther 7:107-112.
  477. Larson LJ, Henningson J, Sharp P, et al. 2011. Efficacy of the canine influenza virus H3N8 vaccine to decrease severity of clinical disease after cochallenge with canine influenza virus and Streptococcus equi subsp. zooepidemicus. Clin Vaccine Immunol 18:559-564.
  478. Larson LJ, Sawchuck S, Schultz RD. 2003. Duration of vaccinal immunity in a population of clinic dogs, abstract no 58. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13-18, Guelph, Ontario, Canada.
  479. Larson LJ, Schultz RD. 1996. Closing the window of susceptibility. Top Vet Med 7:22-26.
  480. Larson LJ, Schultz RD. 1996. High-titer canine parvovirus vaccine: serologic response and challenge of immunity study. Vet Med 88:210-218.
  481. Larson LJ, Schultz RD. 1997. Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection. Am J Vet Res 58:360-363.
  482. Larson LJ, Schultz RD. 2003. Observations on the canine immune response to Leptospira sp. vaccines, abstract no 61. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13–18, Guelph, Ontario, Canada.
  483. Larson LJ, Schultz RD. 2006. Effect of vaccination with recombinant canine distemper virus vaccine immediately before exposure under shelter-like conditions. Vet Ther 7:113-118.
  484. Larson LJ, Schultz RD. 2007. Three-year duration of immunity in dogs vaccinated with a canarypox-vectored recombinant canine distemper virus vaccine. Vet Ther 8:101-106.
  485. Larson LJ, Schultz RD. 2007. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine. Vet Ther 8:305-310.
  486. Larson LJ, Schultz RD. 2008. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther 9:94-101.
  487. Larson RL, Bradley JS. 1996. Immunologic principles and immunization strategy. Compend Contin Educ Pract Vet 18:963-971.
  488. Lasky T, Terracciano GJ, Magder L, et al. 1998. The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339:1797-1802.
  489. Lau RCH, Halliday AJ, Davies H. 1992. Evaluation of the immunogenicity of attenuated feline calicivirus vaccines by ELISA. Vet Microbiol 31:139-146.
  490. Lechner ES, Crawford PC, Levy JK, et al. 2010. Prevalence of protective antibody titers for canine distemper virus and canine parvovirus in dogs entering a Florida animal shelter. J Am Vet Med Assoc 236:1317-1321.
  491. Lednicky JA, Dubach J, Kinsel M, et al. 2004. Genetically distinct American canine distemper virus lineages have recently caused epizootics with somewhat different characteristics in raccoons living around a large suburban zoo in the USA. Virol J 1:2.
  492. Lee C, Jung K, Oh J, et al. 2010. Protective efficacy and immunogenicity of an inactivated avian-origin H3N2 canine influenza vaccine in dogs challenged with the virulent virus. Vet Microbiol 143:184-188.
  493. Lee IT, Levy JK, Gorman SP, et al. 2002. Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats. J Am Vet Med Assoc 220:620-622.
  494. Legendre AM, Hawks DM, Sebring R, et al. 1991. Comparison of the efficacy of three commercial feline leukemia virus vaccines in a natural challenge exposure. J Am Vet Med Assoc 199:1456-1462.
  495. Legendre AM, Mitchener K, Potgieter L. 1990. Efficacy of a feline leukemia virus vaccine in a natural exposure challenge. J Vet Intern Med 4:92-98.
  496. Lehmann R, Franchini M, Aubert A, et al. 1991. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine. J Am Vet Med Assoc 199:1446-1452.
  497. Lehr C, Jayappa H, Erskine J, et al. 2008. Demonstration of 1-year duration of immunity for attenuated Bordetella bronchiseptica vaccines in dogs. Vet Ther 9:257-262.
  498. Leifer CE, Page RL, Matus RE, et al. 1987. Proliferative glomerulonephritis and chronic active hepatitis with cirrhosis associated with Corynebacterium parvum immunotherapy in a dog. J Am Vet Med Assoc 180:78-80.
  499. Lembo T, Hampson K, Kaare MT, et al. 2010. The feasibility of canine rabies elimination in Africa: dispelling doubts with data. PLoS Negl Trop Dis 4:e626.
  500. Leschnik MW, Kirtz G, Khanakah G, et al. 2010. Humoral immune response in dogs naturally infected to Borrelia burgdorferi sensu lato and in dogs after immunization with a Borrelia vaccine. Clin Vaccine Immunol 17:828-835.
  501. Lester S, Clemett T, Burt A. 1996. Vaccine site-associated sarcomas in cats: clinical experience and a laboratory review (1982–1993). J Am Anim Hosp Assoc 32:91-95.
  502. Levy JK, Crawford PC, Collante WR, et al. 2001. Use of adult cat serum to correct failure of passive transfer in kittens. J Am Vet Med Assoc 219:1401-1405.
  503. Levy JK, Crawford PC, Kusuhara H, et al. 2008. Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats. J Vet Intern Med 22:330-334.
  504. Levy JK, Crawford PC, Slater MR. 2004. Effect of vaccination against feline immunodeficiency virus on results of serologic testing in cats. J Am Vet Med Assoc 225:1558-1561.
  505. Levy JK, Lappin MR, Glaser AL, et al. 2011. Prevalence of infectious diseases in cats and dogs rescued following Hurricane Katrina. J Am Vet Med Assoc 238:311-317.
  506. Levy JK, Marsh A. 1992. Isolation of calicivirus from the joint of a kitten with arthritis. J Am Vet Med Assoc 201:753-755.
  507. Levy SA, Clark KK, Glickman LT. 2005. Infection rates in dogs vaccinated and not vaccinated with an OspA Borrelia burgdorferi vaccine in a Lyme disease-endemic area of Connecticut. Int J Appl Res Vet Med 3:1-5.
  508. Levy SA, Millership J, Glover S, et al. 2010. Confirmation of presence of Borrelia burgdorferi outer surface protein C antigen and production of antibodies to Borrelia burgdorferi outer surface protein C in dogs vaccinated with a whole-cell Borrelia burgdorferi bacterin. Int J Appl Res Vet Med 8:123-128.
  509. Lewcock P, Bragg C. 1998. Importance of vaccination. Vet Rec 143:668.
  510. Liao C, McVey DS. 1995. Immunity at mucosal surfaces. Vet Scope 3:1-2.
  511. Lima KM, dos Santos SA, Rodrigues JM, et al. 2004. Vaccine adjuvant: it makes the difference. Vaccine 22:2374-2379.
  512. Linde A, Ross CR, Davis EG, et al. 2008. Innate immunity and host defense peptides in veterinary medicine. J Vet Intern Med 22:247-265.
  513. Littman MP. 1997. Why I don't use Lyme disease vaccines. Compend Contin Educ Pract Vet 19:1269-1275.
  514. Lodmell DL, Ewalt LC, Parnell MJ, et al. 2006. One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus. Vaccine 24:412-416.
  515. Lodmell DL, Parnell MJ, Bailey JR, et al. 2002. One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine 20:838-844.
  516. Lodmell DL, Parnell MJ, Weyhrich JT, et al. 2003. Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody. Vaccine 21(25-26):3998-4002.
  517. Loeffler IK, Howard J, Montali RJ, et al. 2007. Serosurvey of ex sito giant pandas (Ailuropoda melanoleuca) and red pandas (Ailurus fulgens) in China with implications for species conservation. J Zoo Wildl Med 38:559-566.
  518. Luft BJ, Dunn JJ, Lawson CL. 2002. Approaches toward the directed design of a vaccine against Borrelia burgdorferi. J Infect Dis 185(Suppl 1):S46-S51.
  519. Lukert W. 2002. Study on the efficacy of an FIP vaccine under shelter-like conditions. Thesis. Veterinary Medical School, University of Giessen. http://bib.uni-giessen.de/ghtm/2002/uni/d020045.htm.
  520. Lutz H, Addie D, Belak S, et al. 2009. Feline leukaemia. J Feline Med Surg 11:565-574.
  521. Lynn RC. 1986. How to control canine infectious tracheobronchitis through vaccination. Vet Med 81:544-550.
  522. Ma J, Hine PM, Clough ER, et al. 1996. Safety, efficacy and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine. Vaccine 14:1366-1374.
  523. MacDonald K, Levy JK, Tucker SJ, et al. 2004. Effects of passive transfer of immunity on results of diagnostic tests for antibodies against feline immunodeficiency virus in kittens born to vaccinated queens. J Am Vet Med Assoc 225:1554-1557.
  524. MacIntire DK, Smith-Carr S, Jones R, et al. 1999. Treatment of dogs naturally infected with canine parvovirus with lyophilized canine IgG, p 721. In Proceedings of the 17th ACVIM Annual Meeting, Chicago.
  525. Macy DW. 1995. The potential role and mechanisms of FeLV vaccine-induced neoplasms. Semin Vet Med Surg 10:234-237.
  526. Macy DW. 1997. Vaccine adjuvants. Semin Vet Med Surg 12:206-211.
  527. Macy DW. 1999. Current understanding of vaccination site-associated sarcomas in the cat. J Feline Med Surg 1:15-21.
  528. Macy DW. 2003. Personal communication. Colorado State University, Fort Collins, CO.
  529. Macy DW. 2004. Feline vaccine-associated sarcomas: progress? Anim Health Res Rev 5:287-289.
  530. Macy DW, Bergman PJ, Powers B. 1994. Postvaccination reactions associated with three rabies and three leukemia virus vaccines in cats. Proc Annu Meet Vet Cancer Soc 14:90-91.
  531. Macy DW, Bergman PJ. 1995. Vaccine-associated sarcomas in cats. Feline Pract 23:24-27.
  532. Macy DW, Chretin J. 1999. Local postvaccinal reactions of a recombinant rabies vaccine. Vet Forum 16:44-49.
  533. Macy DW, Couto CG. 2001. Prevention and treatment of injection-site sarcomas. J Feline Med Surg 3:169-170.
  534. Macy DW, Hendrick MJ. 1996. The potential role of inflammation in the development of postvaccinal sarcomas in cats. Vet Clin North Am Small Anim Pract 26:103-109.
  535. Madewell BR, Griffey SM, McEntee MC, et al. 2001. Feline vaccine-associated fibrosarcomas: an ultrastructural study of 20 tumors (1996–1999). Vet Pathol 38:196-202.
  536. Madsen LM. 2008. Vaccine transport, storage, and handling. Vet Tech 29(3).
  537. Makoschey B, Beer M. 2004. Assessment of the risk of transmission of vaccine viruses by using insufficiently cleaned injection devices. Vet Rec 155:563-564.
  538. Malik R, Dowden M, Davis PE, et al. 1995. Concurrent juvenile cellulitis and metaphyseal osteopathy: an atypical canine distemper virus syndrome. Aust Vet Pract 25:62-65.
  539. Malik R, Kendall K, Cridland J, et al. 1997. Prevalences of feline leukemia virus and feline immunodeficiency virus infections in cats in Sydney. Aust Vet J 75:323-327.
  540. Manser P. 2003. Preliminary results of the dog and cat exotic disease surveillance scheme. Vet Rec 153:220.
  541. Mansfield KL, Burr PD, Snodgrass DR, et al. 2004. Factors affecting the serological response of dogs and cats to rabies vaccination. Vet Rec 154:423-426.
  542. Mansfield PD. 1996. Vaccination of dogs and cats in veterinary teaching hospitals in North America. J Am Vet Med Assoc 208:1242-1247.
  543. Marciani DJ, Kensil CR, Beltz GA, et al. 1991. Genetically engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine 9:89-96.
  544. Marsella R. 2000. Vaccination reactions dampened. Vet Forum May:20.
  545. Martano M, Morello E, Buracco P. 2011. Feline injection-site sarcoma: past, present and future perspectives. Vet J 188:136-141.
  546. Martella V, Blixenkrone-Moller M, Elia G, et al. 2011. Lights and shades on an historical vaccine canine distemper virus, the Rockborn strain. Vaccine 29:1222-1227.
  547. Martin ML. 1985. Canine coronavirus enteritis and a recent outbreak following modified-live virus vaccination. Compend Contin Educ Pract Vet 7:1013-1016.
  548. Masubuchi K, Wakatsuki A, Iwamoto K, et al. 2010. Efficacy of a new inactivated Chlamydophila felis vaccine in experimentally-infected cats. J Feline Med Surg 12:609-613.
  549. Masubuchi K, Wakatsuki A, Iwamoto K, et al. 2010. Immunological and genetic characterization of feline caliciviruses used in the development of a new trivalent inactivated vaccine in Japan. J Vet Med Sci 72:1189-1194.
  550. Matteucci D, Pistello M, Mazzetti P, et al. 1997. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection by a fixed-cell vaccine against cell free and cell-associated challenge differs in duration and is not easily boosted. J Virol 71:8368-8376.
  551. Mayer P, Werner FJ, Lam C, et al. 1990. In vitro and in vivo activity of human recombinant granulocyte-macrophage colony-stimulating factor in dogs. Exp Hematol 18:1026-1033.
  552. McCabe VJ, Tarpey I, Spibey N. 2002. Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine 20:2454-2462.
  553. McCaw DL. 1991. Advances in therapy for retroviral infections, pp 21-25. In August J (ed): Consultations in feline internal medicine, ed 2. WB Saunders, Philadelphia.
  554. McCaw DL, Boon GD. 1998. Immunomodulation therapy for FeLV: a comparison of two agents [abstract]. In Proceedings of the American College of Veterinary Internal Medicine, San Diego.
  555. McCaw DL, Boon GB, Jergens AE, et al. 1998. Immunomodulation therapy for FeLV: a comparison of two agents. J Vet Intern Med 12:229.
  556. McCaw DL, Boon GB, Jergens AE, et al. 2001. Immunomodulation therapy for feline leukemia virus infection. J Am Anim Hosp Assoc 37:356-363.
  557. McCaw DL, Tate D, Dubovi EJ, et al. 1997. Early protection of puppies against canine parvovirus: a comparison of two vaccines. J Am Anim Hosp Assoc 33:244-250.
  558. McGaw DL, Thompson M, Tate D, et al. 1998. Serum distemper virus and parvovirus antibody titers among dogs brought to a veterinary hospital for revaccination. J Am Vet Med Assoc 213:72-75.
  559. McEntee MC, Page RL. 2001. Feline vaccine-associated sarcomas. J Vet Intern Med 15:176-182.
  560. McGill L. 2000. Feline injection site-associated sarcoma. Vet Forum Aug:36-43.
  561. McGill L. 2000. Longtime support for vaccine restraint. Vet Forum Sep:32.
  562. McGill LD. 1993. Vaccine associated sarcomas. Facing a real dilemma. Vet Forum Jun:26-28.
  563. McLaughlin MA. 2004. Additional comments on vaccination protocols. J Am Vet Med Assoc 224:197-198; author reply p 198.
  564. McLaughlin MA. 2004. Comments on conclusions of serologic response studies. J Am Vet Med Assoc 224:662; author reply pp 662-663.
  565. McMillen GL, Briggs DJ, McVey DS, et al. 1995. Vaccination of racing greyhounds: effects on humoral and cellular immunity. Vet Immunol Immunopathol 49:101-113.
  566. McNiel EA. 2001. Vaccine-associated sarcomas in cats: a unique cancer model. Clin Orthop 382:21-27.
  567. McReynolds C, Macy D. 1997. Feline infectious peritonitis. Part II. Treatment and prevention. Compend Contin Educ Pract Vet 19:1111-1117.
  568. McVey DS, Kennedy M. 2008. Vaccines for emerging and re-emerging viral diseases of companion animals. Vet Clin Small Anim 38:903-917.
  569. Mech LD, Goyal SM, Paul WJ, et al. 2008. Demographic effects of canine parvovirus on a free-ranging wolf population over 30 years. J Wildl Dis 44:824-836.
  570. Meloen RH, Hamilton WD, Casal JI, et al. 1998. Edible vaccines. Vet Q 20(Suppl 3):S92-S95.
  571. Merial Lyme vaccine (product insert). Merial Inc., Duluth, GA.
  572. Meuer SC, Dumann H, Buschenfelde KM, et al. 1989. Low dose interleukin-2 induces systemic immune responses against HBs Ag in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-17.
  573. Meunier PC, Cooper BJ, Appel MJG, et al. 1985. Pathogenesis of canine parvovirus enteritis: sequential virus distribution and passive immunization studies. Vet Pathol 22:617-624.
  574. Miliauskas JR, Mukherjee T. 1993. Postimmunization (vaccination) injection-site reactions. Am J Surg Pathol 17:516-524.
  575. Mills RM. 2003. The pros and cons of vaccinating the dog population against canine coronavirus and one of the serovars of Leptospira interrogans. Aust Vet J 81:531.
  576. Ministry of Agriculture (United Kingdom). 2011. http://ww2.defra.gov.uk. Accessed 3/11/11.
  577. Mittleman E, Gaynor JS. 2000. A brief overview of the analgesic and immunologic effects of acupuncture in domestic animals. J Am Vet Med Assoc 217:1201-1205.
  578. Miyamoto T, Taura Y, Une S, et al. 1995. Immunological responses after vaccination pre- and post-surgery in dogs. J Vet Med Sci 57:29-32.
  579. Miyazawa T. 2010. Endogenous retroviruses as potential hazards for vaccines. Biologicals 38:371-376.
  580. Miyazawa T, Yoshikawa R, Golder M, et al. 2010. Isolation of an infectious endogenous retrovirus in a proportion of live attenuated vaccines for pets. J Virol 84:3690-3694.
  581. Mochizuki M, Horiuchi M, Hiragi H, et al. 1996. Isolation of canine parvovirus from a cat manifesting clinical signs of feline panleukopenia. J Clin Microbiol 34:2101-2105.
  582. Molano I, Alonso MG, Redondo E, et al. 2003. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92:1-13.
  583. Molrine DC, Siber GR, Samra Y, et al. 1999. Normal IgG and impaired IgM responses to polysaccharide vaccines in asplenic patients. J Infect Dis 179:513-517.
  584. Moore GE, DeSantis-Kerr AC, Guptill LF, et al. 2007. Adverse events after vaccine administration in cats: 2,560 cases (2002–2005). J Am Vet Med Assoc 231:94-100.
  585. Moore GE, Frana TS, Guptill LF, et al. 2005. Postmarketing surveillance for dog and cat vaccines: new resources in changing times. J Am Vet Med Assoc 227:1066-1069.
  586. Moore GE, Glickman LT. 2004. A perspective on vaccine guidelines and titer tests for dogs. J Am Vet Med Assoc 224:200-203.
  587. Moore GE, Glickman NW, Ward MP, et al. 2005. Incidence of and risk factors for adverse events associated with distemper and rabies vaccine administration in ferrets. J Am Vet Med Assoc 226:909-912.
  588. Moore GE, Guptill LF, Ward MP, et al. 2005. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc 227:1102-1108.
  589. Moore GE, HogenEsch H. 2010. Adverse vaccinal events in dogs and cats. Vet Clin Small Anim 40:393-407.
  590. Morein B, Blomqvist G, Hu K. 2007. Immune responsiveness in the neonatal period. J Comp Pathol 137:S27-S31.
  591. Moroz S. 1999. Common sense on vaccines. Vet Forum Jul:12.
  592. Morresey P. 2004. Reproductive effects of canine herpesvirus. Compend Contin Educ Pract Vet 26:804-810.
  593. Morrison WB, Starr RM, Vaccine-Associated Feline Sarcoma Task Force. 2001. Vaccine-associated feline sarcoma. J Am Vet Med Assoc 218:697-702, available at http://www.avma.org/vafstf/vafstf01.asp. Accessed 8/7/11.
  594. Mouzin DE, Lorenzen MJ, Haworth JD, et al. 2004. Duration of serologic response to five viral antigens in dogs. J Am Vet Med Assoc 224:55-60.
  595. Mouzin DE, Lorenzen MJ, Haworth JD, et al. 2004. Duration of serologic response to three viral antigens in cats. J Am Vet Med Assoc 224:61-66.
  596. Mueller RS, Fieseler KV, Bettenay SV, et al. 2002. Influence of long-term treatment with tetracycline and niacinamide on antibody production in dogs with discoid lupus erythematosus. Am J Vet Res 63:491-494.
  597. Mullen D. 1998. A view from the trenches: a practitioner's comments on the role of vaccines in preventative health care for pets. Compend Contin Educ Pract Vet 20(Suppl):25-27.
  598. Muntener CR, Bruckner L, Sturer A, et al. 2009. Vigilance for veterinary medicinal products: declarations of adverse reactions in the year 2008. Schweiz Arch Tierheilkd 151:583-590.
  599. Muntener CR, Bruckner L, Sturer A, et al. 2010. Vigilance for veterinary medicinal products: declarations of adverse reactions in the year 2009. Schweiz Arch Tierheilkd 152:575-583.
  600. Murray KO, Arguin PM. 2000. Decision-based evaluation of recommendations for preexposure rabies vaccination. J Am Vet Med Assoc 216:188-191.
  601. Murray KO, Holmes KC, Hanlon CA. 2009. Rabies in vaccinated dogs and cats in the United States, 1997–2001. J Am Vet Med Assoc 235:691-695.
  602. Nakamura K, Sakamoto M, Ikeda Y, et al. 2001. Pathogenic potential of canine parvovirus types (CPV) 2a and 2c in domestic cats. Clin Diagn Lab Immun 8:663-668.
  603. Nakima S, Tamaka M, Tamaka T. 1990. Effects of halothane or pentobarbital anesthesia on blastogenesis of peripheral blood lymphocytes in dogs. Jpn J Vet Anesth Surg 21:71-77.
  604. Nandi S, Angazhagan R, Kumar M. 2010. Molecular characterisation and nucleotide sequence analysis of canine parvovirus strains in vaccines in India. Vet Ital 46:69-81.
  605. Nara PL, Krakowka S, Powers TE. 1979. Effects of prednisolone on the development of immune responses to canine distemper virus in beagle pups. Am J Vet Res 40:1742-1747.
  606. National Association of State Public Health Veterinarians, Inc. 2008. Compendium of animal rabies prevention and control. http://www.nasphv.org/Documents/RabiesCompendium.pdf. Accessed 3/11/11.
  607. Nelson RS, Mshar PA, Cartter ML, et al. 1998. Public awareness of rabies and compliance with pet vaccination laws in Connecticut, 1993. J Am Vet Med Assoc 212:1552-1555.
  608. Nesseler A, Baumgärtner W, Gaedke K, et al. 1997. Abundant expression of viral nucleoprotein in mRNA and restricted translation of the corresponding viral protein in inclusion body polioencephalitis of canine distemper. J Comp Pathol 116:291-301.
  609. New JC, Reinemeyer CR, Burr JHH. 1997. Results of a survey to assess knowledge and expectations of veterinarians and their clients regarding heartworm preventatives and vaccinations in dogs. J Am Vet Med Assoc 211:434-437.
  610. Nicholas BL, Brennan FR, Hamilton WDO, et al. 2003. Effect of priming/booster immunisation protocols on immune response to canine parvovirus peptide induced by vaccination with a chimaeric plant virus construct. Vaccine 21:2441-2447.
  611. Nicholas BL, Brennan FR, Martinez-Torrecuadrada JL, et al. 2002. Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. Vaccine 20:2727-2734.
  612. Nichols PR, Morris DO, Beale KM. 2001. A retrospective study of canine and feline cutaneous vasculitis. Vet Dermatol 12:255-264.
  613. Nishikawa Y, Mikami T, Nagasawa H. 2002. Vaccine development against Neospora caninum infection. J Vet Med Sci 64:1-5.
  614. Nolen RS. 2000. Practitioner input sought at vaccine workshop. J Am Vet Med Assoc 216:1893.
  615. Norsworthy GD. 1996. Interferon-alpha as an immunostimulant. Vet Forum Oct:27.
  616. Norsworthy GD. 1999. Another perspective on the vaccination controversy: proposed changes in the standard feline vaccination protocol. Vet Med Aug:727-735.
  617. Norsworthy GD. 1999. Another perspective on the vaccination controversy: redefining the annual visit. Vet Med :736-742.
  618. Norsworthy GD. 1999. Questions efficacy of vaccinating cats at 3-year intervals. Am J Vet Res 60:918-919.
  619. Norsworthy GD. 2004. Calls for vaccine challenge studies. J Am Vet Med Assoc 224:1069; author reply, pp 1069-1070.
  620. Ntafis V, Xylouri E, Kalli I, et al. 2010. Characterization of canine parvovirus 2 variants circulating in Greece. J Vet Diagn Invest 22:737-740.
  621. Obradovich JE, Ogilvie GK, Stadler-Morris S, et al. 1993. Effect of recombinant canine granulocyte colony-stimulating factor on peripheral blood neutrophil counts in normal cats. J Vet Intern Med 7:65-67.
  622. Ogilvie G. 2002. Vaccines and injection-site sarcoma: ethical demand for dialogue. Vet Forum Feb:45-49.
  623. Ogra PL, Faden H, Welliver RC. 2001. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14:430-445.
  624. Ohmori K, Masuda K, DeBoer DJ, et al. 2007. Immunoblot analysis for IgE-reactive components of fetal calf serum in dogs that developed allergic reactions after non-rabies vaccination. Vet Immunol Immunopathol 115:166-171.
  625. Ohmori K, Masuda K, Maeda S, et al. 2005. IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination. Vet Immunol Immunopathol 104:249-256.
  626. Ohmori K, Masuda K, Sakaguchi M, et al. 2002. A retrospective study on adverse reactions to canine vaccines in Japan. J Vet Med Sci 64:851-853.
  627. Ohmori K, Sakaguchi M, Kaburagi Y, et al. 2005. Suspected allergic reactions after vaccination in 85 dogs in Japan. Vet Rec 156:87-88.
  628. Olsen CW. 1999. Vaccination of cats against emerging and reemerging zoonotic pathogens. Adv Vet Med 41:333-346.
  629. Olson ME, Ceri H, Morch DW. 2000. Giardia vaccination. Parasitol Today 16:213-217.
  630. Olson ME, Hannigan CJ, Gaviller PF, et al. 2001. The use of a Giardia vaccine as an immunotherapeutic agent in dogs. Can Vet J 42:865-868.
  631. Olson ME, Morck DW, Ceri H. 1996. The efficacy of a Giardia lamblia vaccine in kittens. Can J Vet Res 60:249-256.
  632. Olson P, Hedhammar A, Klingeborn B. 1996. Canine parvovirus infection, canine distemper and infectious canine hepatitis: inclination to vaccinate and antibody response in the Swedish dog population. Acta Vet Scand 37:433-444.
  633. Opal SM, Wherry JC, Grint P. 1998. Interleukin-10: potential benefits and possible risks in clinical infectious disease. Clin Infect Dis 27:1497-1507.
  634. Oppenheim JJ, Biragyn A, Kwak LW, et al. 2003. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 62(Suppl 2):ii17-ii21.
  635. Opriessnig T, Zhang H, Mohn U, et al. 2010. Comparison of five enzyme immunoassays (EIAs) for detection of anti hepatitis E virus (HEV) immunoglobulin G (IgG) in swine. In AAVLD 53rd Annual Conference, Minneapolis.
  636. Orr CM, Gaskell CJ. 1978. Interaction of a combined feline viral rhinotracheitis-feline calicivirus vaccine and the FVR carrier state. Vet Rec 103:200-202.
  637. Ortloff A, Moran G, Olavarria A, et al. 2010. Membranoproliferative glomerulonephritis possibly associated with over-vaccination in a cocker spaniel. J Small Anim Pract 51:499-502.
  638. Osorio JE, Tomlinson CC, Frank RS, et al. 1999. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 17:1109-1116.
  639. Ottiger HP, Neimeier-Förster M, Stärk KDC, et al. 2006. Serological responses of adult dogs to revaccination against distemper, parvovirus and rabies. Vet Rec 159:7-12.
  640. Otto CM, Drobatz KJ, Soter C. 1997. Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis. J Vet Intern Med 11:65-70.
  641. Overall KL. 2000. Rabies vaccine labeling and wolf hybrid. J Am Vet Med Assoc 216:20.
  642. Oxford JS. 2008. The end of the beginning: Vaccines for the next 25 years. Vaccine 26:6179-6182.
  643. Oyedele OI, Oluwayelu DO, Cadmus SI, et al. 2004. Protective levels of canine distemper virus antibody in an urban dog population using plaque reduction neutralization test. Onderstepoort J Vet Res 71:227-230.
  644. Ozkul A, Sancak AA, Güngör E, et al. 2004. Determination and phylogenetic analysis of canine distemper virus in dogs with nervous symptoms in Turkey. Acta Vet Hung 52:125-132.
  645. Padrid PA, Qin Y, Wells TNC, et al. 1998. Sequence and structural analysis of feline interleukin-5 cDNA. Am J Vet Res 59:1263-1269.
  646. Palese P, García-Sastre A. 2002. New directions in vaccine research. J Clin Invest 109:1517-1518.
  647. Palmquist RE, Kornheiser KM, Dodds WJ. 2004. More on cat and dog vaccinations. J Am Vet Med Assoc 224:1580-1581.
  648. Pardo MC, Bauman JE, Mackowiak M. 1997. Protection of dogs against canine distemper by vaccination with a canary pox virus recombinant expressing virus fusion and hemagglutinin glycoproteins. Am J Vet Res 58:833-836.
  649. Pardo MC, Mackowiak M. 1997. Efficacy of a new canine origin, modified live virus vaccine against canine coronavirus. Research report. Rhone Merieux, Athens, GA.
  650. Pardo MC, Mackowiak M. 1997. Safety of a new modified live virus vaccine against canine coronavirus. Research report. Rhone Merieux, Athens, GA.
  651. Pardo MC, Tanner P, Bauman J, et al. 2007. Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus. J Comp Pathol 137:S72-S75.
  652. Partidos CD, Beignon AS, Mawas F, et al. 2003. Immunity under the skin: potential application for topical delivery of vaccines. Vaccine 21:776-780.
  653. Pastyoret PP. 2007. Challenges and issues of early life vaccination in animals and humans. J Comp Pathol 137:S2-S3.
  654. Patel JR, Heldens JGM. 2009. Review of companion animal viral diseases and immunoprophylaxis. Vaccine 27:491-504.
  655. Patronek GJ, Glickman LT, Hohnson R, et al. 1995. Canine distemper infection in pet dogs: II. A case control study of risk factors during a suspected outbreak in Indiana. J Am Anim Hosp Assoc 31:230-235.
  656. Patterson EV, Reese MJ, Tucker SJ, et al. 2007. Effect of vaccination on parvovirus antigen testing in kittens. J Am Vet Med Assoc 230:359-363.
  657. Paul MA, Appel M, Barrett R, et al. 2003. Report of the American Animal Hospital Association (AAHA) canine vaccination task force: executive summary and 2003 canine vaccine guidelines and recommendations. J Am Anim Hosp Assoc 39:119-131.
  658. Paul MA, Carmichael LE, Childers H, et al. 2006. 2006 AAHA Canine Vaccine Guidelines, Revised. J Am Anim Hosp Assoc 42:80-89.
  659. Peacock GV. 1966. Agents for passive immunization against canine distemper. J Am Vet Med Assoc 149:633-639.
  660. Pedersen NC. 1993. Immunogenicity and efficacy of a commercial feline leukemia virus vaccine. J Vet Intern Med 7:34-39.
  661. Pedersen NC, Boyle JF, Floyd K, et al. 1981. An enteric coronavirus infection of cats and its relationship to feline infectious peritonitis. Am J Vet Res 42:368-377.
  662. Pedersen NC, Emmons RW, Selcer R, et al. 1978. Rabies vaccine virus infection in three dogs. J Am Vet Med Assoc 172:1092-1096.
  663. Pedersen NC, Emmons RW, Selcer R, et al. 1978. Rabies vaccine virus infection in three dogs. J Am Vet Med Assoc 172:1092-1096.
  664. Pedersen NC, Johnson L. 1991. Comparative efficacy of three commercial feline leukemia virus vaccines against methylprednisolone acetate. Augmented oronasal challenge exposure with virulent virus. J Am Vet Med Assoc 199:1453-1455.
  665. Perrin P, Jacob Y, Aguilar-Sétien A, et al. 1999. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 18:479-486.
  666. Perrone D, Bender S, Niewiesk S. 2010. A comparison of the immune responses of dogs exposed to canine distemper virus (CDV)—differences between vaccinated and wild-type virus exposed dogs. Can J Vet Res 74:214-217.
  667. Pet Relocation. 2011. Information on shipment of pets. http://www.petrelocation.com.
  668. Pet Travel Inc. 2010. Pet quarantine, pet travel, pet immigration information. http://www.pettravel.com/passportnew.cfm. Accessed 4/22/11.
  669. Phillips BS, Padilla ML, Dickerson EB, et al. 1999. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Vet Immunol Immunopathol 70:189-201.
  670. Phillips TR, Jensen JL, Rubino MJ, et al. 1989. Effects of vaccine on the canine immune system. Can J Vet Res 53:154-160.
  671. Phillips TR, Schultz RD. 1987. Failure of vaccine or virulent strains of canine parvovirus to induce immunosuppressive effects on the immune system of the dog. Viral Immunol 1:135-143.
  672. Piscitelli SC, Rodvold KA. 2001. Drug interactions in infectious diseases. Clin Infect Dis 32:1245.
  673. Pistello M, Conti F, Vannucci L. 2010. Novel approaches to vaccination against the feline immunodeficiency virus. Vet Immunol Immunopathol 134:48-53.
  674. Pittman PR. 2002. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 20:S48-S50.
  675. Plotkin SA. 2008. Correlates of vaccine-induced immunity. Vaccine 47:401-409.
  676. Poffenbarger EM, Olson PN, Chandler ML, et al. 1991. Use of adult dog serum as a substitute for colostrum in the neonatal dog. Am J Vet Res 52:1221-1224.
  677. Poirier VJ, Thamm DH, Kurzman ID, et al. 2002. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med 16:726-731.
  678. Pollock RVH. 1981. Canine parvovirus: host response and immunoprophylaxis. Doctoral dissertation. Cornell University, Ithaca, NY.
  679. Pollock RVH, Carmichael LE. 1982. Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J Am Vet Med Assoc 180:37-42.
  680. Pollock RVH, Carmichael LE. 1983. Use of modified live feline panleukopenia virus vaccine to immunize dogs against canine parvovirus. Am J Vet Res 44:169-175.
  681. Pollock RVH, Haffer KN. 1991. Review of the first feline leukemia virus vaccine. J Am Vet Med Assoc 199:1406-1409.
  682. Pollock RVH, Scarlett JM. 1990. Randomized blind trial of a commercial FeLV vaccine. J Am Vet Med Assoc 196:611-615.
  683. Poot J, Janssen LHM, van Kasteren-Westerneng TJ, et al. 2009. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants. Vaccine 27:4439-4446.
  684. Porter CJ, Radford AD, Gaskell RM, et al. 2008. Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a panel of current UK FCV isolates. J Feline Med Surg 10:32-40.
  685. Postorino Reeves NC. 1995. Vaccination against naturally occurring FIP in a single large cat shelter. Feline Pract 23:81-82
  686. Potera C. 2002. Lyme vaccine Lymerix leaves market, but others in wings. ASM News 68:265-266.
  687. Poubanne Y. 2006. DOI and booster vaccination—dealing with the issue at practice level in France. Vet Microbiology 117:86-92.
  688. Poulet H. 2007. Alternative early life vaccination programs for companion animals. J Comp Pathol 137:S67-S71.
  689. Poulet H, Brunet S, Boularand C, et al. 2003. Efficacy of a canarypox virus-vectored vaccine against feline leukemia. Vet Rec 153:141-145.
  690. Poulet H, Guigal PM, Soulier M, et al. 2001. Protection of puppies against canine herpesvirus by vaccination of the dams. Vet Rec 148:691-695.
  691. Poulet H, Jas D, Lemeter C, et al. 2008. Efficacy of a bivalent inactivated non-adjuvanted feline calicivirus vaccine: relation between in vitro cross-neutralization and heterologous protection in vivo. Vaccine 26:3647-3654.
  692. Povey RC. 1979. A review of feline viral rhinotracheitis (feline herpesvirus-1) infection. Comp Immunol Microbiol Infect Dis 2:373-387.
  693. Povey RC. 1999. Vaccination protocols for dogs and cats. Can Vet J 40:7.
  694. Povey RC, Carman PS, Ewert E. 1983. The duration of immunity to an inactivated adjuvanted canine parvovirus vaccine. Can Vet J 24:245-248.
  695. Pratelli A, Tinelli A, Decaro N, et al. 2003. Efficacy of an inactivated canine coronavirus vaccine in pups. New Microbiol 26:151-155.
  696. Pratelli A, Tinelli A, Decaro N, et al. 2004. Safety and efficacy of a modified-live canine coronavirus vaccine in dogs. Vet Microbiol 99:43-49.
  697. Pravieux JJ, Poulet H, Charreyre C, et al. 2007. Protection of newborn animals through maternal immunization. J Comp Pathol 137:S32-S34.
  698. Priestnall S, Erles K. 2011. Streptococcus zooepidemicus: an emerging canine pathogen. Vet J 188:142-148.
  699. Priosoeryanto B, Tateyama S, Yamaguchi R, et al. 1995. Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro. Can J Vet Res 59:67-69.
  700. Pubanne Y. 2006. DOI and booster vaccination—dealing with the issue at practice level in France. Vet Microbiol 117:86-92.
  701. 697a. Quintana AM, Hussey SB, Burr EC, et al. 2011. Evaluation of infectivity of a canine lineage H3N8 influenza A virus in ponies and in primary equine respiratory epithelial cells. Am J Vet Res 72:1071-1078.
  702. Radford A. 2010. The hitchhiker's guide to dog and cat vaccination. J Small Anim Pract 51:293-294.
  703. Radford AD, Addie D, Belák S, et al. 2009. Feline calicivirus infection. ABCD guidelines on prevention and management. J Feline Med Surg 11:556-564.
  704. Radford AD, Dawson S, Coyne KP, et al. 2006. The challenge for the next generation of feline calicivirus vaccines. Vet Microbiol 117:14-18.
  705. 700a. Raghavan R, Brenner K, Higgins J, et al. 2011. Evaluations of land cover risk factors for canine leptospirosis: 94 cases (2002–2009). Prev Vet Med 1001:241-249.
  706. Ramey DW, Rollin BE. 2001. Ethical aspects of proof and “alternative” therapies. J Am Vet Med Assoc 218:343-346.
  707. Ramnial V, Kosmider R, Aylan O, et al. 2010. Quantitative risk assessment to compare the risk of rabies entering the UK from Turkey via quarantine, the Pet Travel Scheme and the EU Pet Movement Policy. Epidemiol Infect 138:1114-1125.
  708. Ramon ME, Slater MR, Ward MP. 2010. Companion animal knowledge, attachment and pet cat care and their associations with household demographics for residents of a rural Texas town. Prev Vet Med 94:251-263.
  709. Rassnick KM, Moore AS, Northrup NC, et al. 2006. Am J Vet Res 67(3):510-516.
  710. Rath BA, Register KB, Wall J, et al. 2008. Persistent Bordetella bronchiseptica pneumonia in an immunocompetent infant and genetic comparison of clinical isolates with kennel cough vaccine strains. Clin Infect Dis 46:905-908.
  711. Reade B, Bowers RG, Begon M, et al. 1998. A model of disease and vaccination for infections with acute and chronic phases. J Theor Biol 190:355-367.
  712. Reed TL, VonMessling V, Cattaneo R, et al. 2003. A comparative study of canine distemper vaccines, abstract no 56. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13-18, Guelph, Ontario, Canada.
  713. Reed TL, VonMessling V, Cattaneo R, et al. 2003. The development of a novel DNA vaccine for canine distemper virus, abstract no 54. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13–18, Guelph, Ontario, Canada.
  714. Reese MJ, Patterson EV, Tucker SJ, et al. 2008. Effects of anesthesia and surgery on serologic responses to vaccination in kittens. J Am Vet Med Assoc 233:116-121.
  715. Reggeti F, Kruth S, Little S, et al. 2003. The variability of feline immunodeficiency virus PCR diagnosis by veterinary laboratories, abstract no 71. In Proceedings of the 3rd International Meeting on Veterinary Vaccine, July 13-18, Guelph, Ontario, Canada.
  716. Register K. 2004. Comparative sequence analysis of Bordetella bronchiseptica pertactin gene (prn) repeat region variants in swine vaccines and field isolates. Vaccine 23:48-57.
  717. Reis AB, Giunchetti RC, Carrillo E, et al. 2010. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends Parasitol 26:341-349.
  718. Resbois A, Coppens A, Poncelet L. 2007. Naturally occurring parvovirus-associated feline hypogranular cerebellar hypoplasia—a comparison to experimentally-induced lesions using immunohistology. Vet Pathol 44:831-841.
  719. Rewerts JM, Cohn LA, McGaw D, et al. 1997. G-CSF levels in parvovirus infected puppies (abstract no 118), p 680. In Proceedings of the American College of Veterinary Internal Medicine, Orlando.
  720. Richards J, Levy, J, Edwards D, et al. 2003. 2001 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Retrovirus Testing and Management. J Feline Med Surg 5:3-10.
  721. Richards J, Rodan I, Elston T, et al. 2001. 2000 Report of the American Association of Feline Practitioners and Academy of Feline Medicine Advisory Panel on Feline Vaccines. J Feline Med Surg 3:47-72.
  722. Richards J, Rodan I, Elston T, et al. 2001. Feline vaccine liability and management. Compend Contin Educ Pract Vet 23:116-126.
  723. Richards J, Rodan I, Elston T, et al. 2001. Feline vaccine selection and administration. Compend Contin Educ Pract Vet 23:71-80.
  724. Richards JR. 1996. Advances in feline health research: impact of recent developments in vaccinology on feline welfare. J Am Vet Med Assoc 208:505-512.
  725. Richards JR. 1998. Education/communication: history and current status. J Am Vet Med Assoc 213:1429-1430.
  726. Richards JR. 1998. Education/communication: history and current status. J Am Vet Med Assoc 213:1429-1430.
  727. Richards JR. 1998. Vaccine-associated feline sarcoma symposium held at AVMA convention. Vet Prod News Oct:10.
  728. Richards JR. 1998. Vaccine-associated feline sarcoma symposium held at AVMA convention. Vet Prod News Oct:10.
  729. Richards JR, Elston TH, Ford RB, et al. 2006. The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel Report. J Am Vet Med Assoc 229:1405-1441. http://www.catvets.com/professionals/guidelines/publications/?Id=176. Accessed 3/12/11.
  730. Richards JR, Starr RM, Childers HE, et al. 2005. Vaccine-Associated Feline Sarcoma Task Force: roundtable discussion. The current understanding and management of vaccine-associated sarcomas in cats. J Am Vet Med Assoc 226:1821-1842.
  731. Richter M, Schudel L, Tobler K, et al. 2009. Clinical, virological, and immunological parameters associated with superinfection of latently with FeHV-1 infected cats. Vet Microbiol 138:205-216.
  732. Rikula U, Nuotio L, Sihvonen L. 2000. Canine distemper virus neutralizing antibodies in vaccinated dogs. Vet Rec 147:598-603.
  733. Roach JM, vanVuuren M, Picard JA. 2010. A serological survey of antibodies to Leptospira species in dogs in South Africa. J S Afr Vet Assoc 81:156-159.
  734. Rojas P, Monahan AM, Schuller S, et al. 2010. Detection and quantification of leptospires in urine of dogs: a maintenance host for the zoonotic disease leptospirosis. Eur J Clin Microbiol Infect Dis 29:1305-1309.
  735. Rosen DK. 1999. The cat vaccination wars. Vet Forum Apr:10-16.
  736. Rosenthal RC, Dworkis AS. 1990. Incidence of and some factors affecting adverse reactions to subcutaneous leukocell. J Am Anim Hosp Assoc 26:283-287.
  737. Roth JA. 1999. Mechanistic bases for adverse vaccine reactions and vaccine failure. Adv Vet Med 41:681-700.
  738. Roth JA, Spicker AR. 2010. Duration of immunity induced by companion animal vaccines. Anim Health Res Rev 11:165-190.
  739. Rottier P, Sutton D. 2006. Preface. Vet Mic 117:1
  740. 734a. Ruch-Gallie RA, Veir JK, Hawley JR, et al. 2011. Results of molecular diagnostic assays targteting feline herpesvirus-1 and feline calicivirus in adult cats administered modified live vaccines. J Fel Med Surg 13:541-545.
  741. Rude TA. 2000. Wanted: vaccine power. Vet Forum Jul:33.
  742. Rudmann DG, VanAlstine WG, Doddy F, et al. 1996. Pulmonary and mediastinal metastases of a vaccination site sarcoma in a cat. Vet Pathol 33:466-469.
  743. Rupprecht CE, Hanlon CA, Blanton J, et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res 2005;111:101-105.
  744. Ryan-Gullahorn J. 1998. Cattery vaccination protocols. Feline Pract 26:14-15.
  745. Saalmüller A. 2006. New understanding of immunological mechanisms. Vet Microbiol 117:32-38.
  746. Saker KE. 2003. Nutritional influences on the immune system in aging felines. Compend Contin Educ Pract Vet 26(Suppl):11-14.
  747. Saker KE. 2006. Nutrition and immune function. Vet Clin Small Anim 36:1199-1224.
  748. Sakulwira K, Vanapongtipacorn P, Theamboonlers A, et al. 2003. Prevalence of canine coronavirus and parvovirus infections in dogs with gastroenteritis in Thailand. Vet Med Czech 6:163-167.
  749. Saliki JT, Mizak B, Flore HP, et al. 1992. Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J Gen Virol 73:369-374.
  750. Sandler I, Teeger M, Best S. 1997. Metastatic vaccine associated fibrosarcoma in a 10-year-old cat. Can Vet J 38:374.
  751. Sawson S. 2007. Guidelines for the vaccination of dogs and cats. J Small Anim Pract 48:483.
  752. Saxton J. 1991. The use of canine distemper nosode in disease control. Int J Vet Homeopathy 5:8-12.
  753. Scarlett JM, Pollock RVH. 1991. Year two of follow-up evaluation of a randomized blind field trial of a commercial feline leukemia virus vaccine. J Am Vet Med Assoc 199:1431-1432.
  754. Schafer-Somi S, Bar-Schadler S, Aurich JE. 2005. Immunoglobulins in nasal secretions of dog puppies from birth to six weeks of age. Res Vet Sci 78:143-150.
  755. Schatzberg SJ, Haley NJ, Burr SC, et al. 2003. Polymerase chain reaction (PCR) amplification of parvoviral DNA from the brains of dogs and cats with cerebellar hypoplasia. J Vet Intern Med 17:538-544.
  756. Scherk M. 1998. CVMA position statement on vaccine protocols ill considered. Can Vet J 39:473-476.
  757. Schetters TP, Scholtes NC, Kleuskens JA. 1996. Not peripheral parasitemia but the level of soluble parasite antigen in plasma correlates with vaccine efficacy against Babesia canis. Parasite Immunol 18:1-6.
  758. Schijns VEJC, Scholtes NC, van Zuilekon HI, et al. 2002. Facilitation of antibody forming responses to viral vaccine antigens in young cats by recombinant baculovirus-expressed feline IFN-γ. Vaccine 20:1718-1724.
  759. Schrauwen E, van Ham L. 1995. Postvaccinal acute polyradiculoneuritis in a young dog. Prog Vet Neurol 6:68-70.
  760. Schultz RD. 2004. Personal communication. University of Wisconsin, Madison, WI.
  761. Schultz RD. 1980. Theory and practice of immunization, pp 1248-1255. In Kirk RW (ed): Current veterinary therapy VII. WB Saunders, Philadelphia.
  762. Schultz RD. 1995. Emerging issues: vaccination strategies for canine viral enteritis, pp 19-24. In Proceedings of the Symposium of Infectious Gastroenteritis, North American Veterinary Conference, Orlando.
  763. Schultz RD. 1997. Personal communication. University of Wisconsin, Madison, WI.
  764. Schultz RD. 1998. Current and future canine and feline vaccination programs. Vet Med Mar:233-252.
  765. Schultz RD. 2004. Personal communication. University of Wisconsin, Madison, WI.
  766. Schultz RD. 2006. Duration of immunity for canine and feline vaccines: a review. Vet Microbiol 117:75-79.
  767. Schultz RD. 2006. Personal observations. University of Wisconsin, Madison, WI.
  768. Schultz RD. No date. Canine distemper and vaccination. Merial brochure. http://ph.merial.com/pet_owners/pdf/news_shcultz.pdf. Accessed 3/11/11.
  769. Schultz RD, Ford RB, Olsen J, et al. 2002. Titer testing and vaccination: a new look at traditional practices. Vet Med 97:1-13.
  770. Schultz RD, Hennington J, Sharp P, et al. 2010. Efficacy of canine influenza virus (H3N8) vaccine in dogs con-infected with CIV and Streptococcus equi zooepidemicus. In Proceedings of the 53rd Annual Conference of the American Association of Veterinary Laboratory Diagnosticians, Nov 10-17, Minneapolis.
  771. Schultz RD, Larson LJ. 1996. The new generation parvovirus vaccines. A comparison study. Compend Contin Educ Pract Vet 18:640-641.
  772. Schultz RD, Thiel B, Mukhtar E, et al. 2010. Age and long-term protective immunity in dogs and cats. J Comp Pathol 142(Suppl 1):S102-S108.
  773. Schultze AE, Frank LA, Hahn KA. 1997. Repeated physical and cytologic characterization of subcutaneous postvaccinal reactions in cats. Am J Vet Res 58:719-724.
  774. Scott FW. 1968. Feline panleukopenia. Doctoral dissertation. Cornell University, Ithaca, NY.
  775. Scott FW. 1987. Immunization against feline coronaviruses. Adv Exp Med Biol 218:569-576.
  776. Scott FW. 1999. Evaluation of risks and benefits associated with vaccination against coronavirus infections in cats. Adv Vet Med 41:347-358.
  777. Scott FW, Corapi WV, Olsen CW. 1992. Evaluation of the safety and efficacy of Primucell-FIP vaccine. Feline Health Top 7:6-8.
  778. Scott FW, Csiza CK, Gillespie JH. 1970. Maternally derived immunity to feline panleukopenia. J Am Vet Med Assoc 156:439-453.
  779. Scott FW, Geissinger C. 1997. Duration of immunity in cats vaccinated with an inactivated feline panleukopenia, herpesvirus, and calicivirus vaccine. Feline Pract 25:12-19.
  780. Scott FW, Geissinger CM. 1999. Long-term immunity in cats vaccinated with an inactivated trivalent vaccine. Am J Vet Res 60:652-658.
  781. Scott FW, Olsen CW, Corapi WV. 1995. Antibody-dependent enhancement of feline infectious peritonitis virus-infection. Feline Pract 23:77-80.
  782. Scott-Moncrieff JC, Azcona-Olivera J, Glickman NW, et al. 2002. Evaluation of antithyroglobulin antibodies after routine vaccination in pet and research dogs. J Am Vet Med Assoc 221:515-521.
  783. Scott-Moncrieff JC, Glickman NW, Glickman LT, et al. 2006. Lack of association between repeated vaccination and thyroiditis in laboratory beagles. J Vet Intern Med 20:818-821.
  784. Sebring RW, Chu HJ, Chavez LG, et al. 1991. Feline leukemia virus vaccine development. J Am Vet Med Assoc 199:1413-1419.
  785. Sessions JK, Greene CE. 2004. Canine leptospirosis: treatment, prevention and zoonosis. Compend Contin Educ Pract Vet 26:700-708.
  786. Shaw CA, Starnbach MN. 2003. Using modified bacterial toxins to deliver vaccine antigens. ASM News 69:384-389.
  787. 780a. Shaw SC, Kent MS, Gordon IK, et al. 2009. Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990–2006). J Am Vet Med Assoc 234:376-380.
  788. Sheets MA, Unger BA, Giggleman GF, et al. 1991. Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats. Mol Biother 3:41-45.
  789. Si W, Zhou S, Wang Z, et al. 2010. A multiplex reverse transcription-nested polymerase chain reaction for detection and differentiation of wild-type and vaccine strains of canine distemper virus. Virol J 7:86-91.
  790. Siedek EM, Schmidt H, Sture GH, et al. 2011. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CVP-2b and CPV-2c. Berl Munch Tierarztl Wochenschr 124:58-64.
  791. Siegrist CA. 2007. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 137:S4-S9.
  792. Siegrist CA. 2007. Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 137:S46-S50.
  793. Sikes RK, Peacock GV, Acha P, et al. 1971. Rabies vaccines: duration of immunity study in dogs. J Am Vet Med Assoc 159:1491-1499.
  794. Simon JC, Saker KE, Thomas E. 2000. Sensitivity of specific immune function tests to acute nutrient deprivation as indicators of nutritional status in a feline model. Nutr Res 20:79-89.
  795. Siwicki AK, Krzyzanowski J, Bartoszcze M, et al. 1998. Adjuvant properties of killed Propionibacterium avidum KP-40 in vaccination of dogs against canine parvovirosis. Dtsch Tierarztl Wochenschr 105:186-190.
  796. Sixt N, Cardoso A, Vallier A, et al. 1998. Canine distemper virus DNA vaccination induces humoral and cellular immunity and protects against a lethal intracerebral challenge. J Virol 72:8472-8476.
  797. Slate D, Algeo TP, Nelson KM, et al. 2009. Oral rabies vaccination in North America: opportunities, complexities, and challenges. PLoS Negl Trop Dis 3:e549.
  798. Slater EA. 1970. The response to measles and distemper virus in immunosuppressed and normal dogs. J Am Vet Med Assoc 156:1762-1766.
  799. Smith CA. 1995. Are we vaccinating too much? J Am Vet Med Assoc 207:421-425.
  800. Abdoel TH, Houwers DJ, Van Dongen AM, et al. 2011. Rapid test for the serodiagnosis of acute canine leptospirosis. Vet Microbiol 150:211-213.
  801. Soma T, Ishii H, Hara K, et al. 2003. Detection of canine distemper virus antigen in canine serum and its application to diagnosis. Vet Rec 153:499-501.
  802. Sommerville LM, Radford AD, Glenn M, et al. 2002. DNA vaccination against feline calicivirus infection using a plasmid encoding the mature capsid protein. Vaccine 20:1787-1796.
  803. Sorensen KC, Kitchell BE, Schaeffer DJ, et al. 2004. Expression of matrix metalloproteinases in feline vaccine site-associated sarcomas. Am J Vet Res 65:373-379.
  804. Spaan W, Vennema H, de Groot R, et al. 1989. Early death after challenge with feline infectious peritonitis virus of kittens immunized with a recombinant vaccines virus expressing the FIPV spike protein, pp 491-495. In Lerner RA, Ginsberg HS, Chanock RM, et al. (eds): Vaccines 89. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  805. Sparkes A. 2010. Feline vaccination protocols: is a consensus emerging? Schweiz Arch Tierheilkd 152(3):135-140.
  806. Sparkes AH. 1997. Feline leukaemia virus: a review of immunity and vaccination. J Small Anim Pract 38:187-194.
  807. Sparkes AH. 2001. Towards a more rational and scientific approach to vaccination. J Feline Med Surg 3:45-46.
  808. Sparkes AH. 2004. Vaccination in cats: which ones, and how often? Vet Rec 154:452.
  809. Sparkes AH, Gruffydd-Jones TJ, Harbour DA. 1994. An appraisal of the value of laboratory tests in the diagnosis of feline infectious peritonitis. J Am Anim Hosp Assoc 30:345-350.
  810. Spickler AR, Roth JA. 2003. Adjuvants in veterinary vaccines: modes of actions and adverse effects. J Vet Intern Med 17:273-281.
  811. Srivastava IK, Liu MA. 2003. Gene vaccines. Ann Intern Med 138:550-559.
  812. Stanley MA, Moore RA, Nicholls PK, et al. 2001. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19:2783-2792.
  813. Starr RM. 1993. Reaction rate in cats vaccinated with a new controlled-titer feline panleukopenia-rhinotracheitis-calicivirus-Chlamydia psittaci vaccine. Cornell Vet 83:311-323.
  814. Starr RM. 1998. Vaccine-associated feline sarcoma task force: a new model for problem solving in veterinary medicine. J Am Vet Med Assoc 213:1428-1429.
  815. Stavisky J, Radford AD, Gaskell R, et al. 2011. A case-control study of pathogen and lifestyle risk factors for diarrhoea in dogs. Prev Vet Med 99:185-192.
  816. Stein JE, Lappin MR. 2002. Efficacy of Giardia vaccination for treatment of giardiasis in cats, abstract no 250, p 798. In Proceedings of the 20th ACVIM Annual Meeting, Dallas.
  817. Steinman RM, Pope M. 2002. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519-1526.
  818. Stephensen CB, Welter J, Thacker SR, et al. 1997. Canine distemper virus (CDV) infection of ferrets as a model for testing morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol 71:1506-1513.
  819. Sterner RT, Meltzer MI, Shwiff SA, et al. 2009. Tactics and economics of wildlife oral rabies vaccination, Canada and the United States. Emerg Infect Dis 15:1176-1184.
  820. Stevens DA. 1998. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 26:1266-1269.
  821. Stevenson A, Roberts M. 2002. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine 20:2325-2335.
  822. Stittelaar KJ, Lacombe V, vanLavieren R, et al. 2010. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine. Vaccine 28:4970-4976.
  823. Stockner PK. 1991. ML vaccine causes immune mediated symptoms in Great Danes. DVM News Mag Jun:92-94.
  824. Stokes CR, Finerty S, Gruffydd-Jones TJ, et al. 1999. Mucosal infection and vaccination against feline immunodeficiency virus. J Biotechnol 73:213-221.
  825. Strasser A, May B, Teltscher A, et al. 2003. Immune modulation following immunization with polyvalent vaccines in dogs. Vet Immunol Immunopathol 94:113-121.
  826. Strasser A, Teltscher A, May B, et al. 2000. Age-related changes in the immune system of German shepherd dogs. Vet Med A Physiol Pathol 47:181-192.
  827. Straubinger RK, Sumers BA, Yung-Fu C, et al. 1997. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 35:111-116.
  828. Straw B. 1978. Decrease in platelet count after vaccination with distemper hepatitis (DH) vaccine. Vet Med Small Anim Clin 73:725-726.
  829. Stretlow L. 2010. Canine influenza vaccine found effective against secondary infections. News release, University of Wisconsin, Madison, WI, July 9.
  830. Stringfellow HF, Howat AJ. 1994. Postimmunization (vaccination) injection site reactions. Am J Surg Pathol 18:1179-1180.
  831. Suepaul SM, Carrington CV, Campbell M, et al. 2010. Study on the efficacy of Leptospira vaccines developed from serovars isolated from Trinidad and comparison with commercial vaccines using a hamster model. Vaccine 28:5421-5426.
  832. Sukhumavasi W, Leephong B, Kaewmaneerat S, et al. 2000. Puppies antibody titre response to canine distemper virus before and after vaccination with a CDV-combined vaccines. Thai J Vet Med 30:13-23.
  833. Suliova J, Benisek Z, Svrcek S, et al. 1997. The effectiveness of inactivated purified and concentrated experimental rabies vaccine for veterinary use: immunogenic activity. Vet Med (Praha) 42:51-56.
  834. Suspected adverse reaction surveillance scheme. 2011. http://search.vmd.gov.uk/search?w=SARSS&asug=. Accessed 4/25/11.
  835. Swaim SF, Riddell KP, McGuire JA. 1993. The effects of acemannan on wound healing models in the dog, abstract no 63. In European Tissue Repair and Wound Healing Society. Amsterdam, The Netherlands.
  836. Swango L, Barta R, Fortney B, et al. 1995. Choosing a canine vaccine regimen: part 1. Canine Pract 20:10-14.
  837. Swango LJ. 1983. Frequently asked questions about CPV disease. Norden News 48:4-10.
  838. Swift J. 2001. The risk of vaccination-the importance of “negative” studies. N Engl J Med 344:372-373.
  839. Symposium III report; Current status of veterinary vaccines. 2010. Vaccine 28:8034-8035.
  840. Taguchi M, Namikawa K, Maruo T, et al. 2010. Antibodies to parvovirus, distemper virus and adenovirus conferred to household dogs using commercial combination vaccines containing Leptospira bacterin. Vet Rec 167:931-934.
  841. Takahashi H. 2001. Need for improved vaccine safety surveillance. Vaccine 19:1004.
  842. Tartaglia J, Jarrett O, Neil JC, et al. 1993. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 67:2370-2375.
  843. Tater KC, Jackson HA, Paps J, et al. 2005. Effects of routine prophylactic vaccination or administration of aluminum adjuvant alone on allergen-specific serum lgE and lgG responses in allergic dogs. Am J Vet Res 66:(9)1572-1577.
  844. Taylor J, Pincus S, Tartaglia J, et al. 1991. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol 65:4263-4274.
  845. Taylor J, Tartaglia J, Riviere M, et al. 1994. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev Biol Stand 82:131-135.
  846. Taylor J, Weinberg R, Tartaglia J, et al. 1992. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus infection (F) and hemagglutinin (HA) glycoproteins. Virology 187:321-328.
  847. Thalwitzer S, Wachter B, Robert N, et al. 2009. Seroprevalences to viral pathogens in free-ranging and captive cheetahs (Acinonyx jubatus) on Namibian farmland. Clin Vaccine Immunol 17(2):232-238.
  848. Tham KM, Studdert MJ. 1987. Antibody and cell-mediated immune responses to feline calicivirus following inactivated vaccine and challenge. J Vet Med B 34:640-654.
  849. Thiry E, Addie D, Belak S, et al. 2009. Feline herpesvirus infection. ABCD guidelines on prevention and management. J Feline Med Surg 11:547-555.
  850. Thiry E, Addie D, Belak S, et al. 2009. H5N1 avian influenza in cats. ABCD guidelines on prevention and management. J Feline Med Surg 11:615-618.
  851. Thiry E, Horzinek MC. 2007. Vaccination guidelines: a bridge between official requirements and the daily use of vaccines. Rev Sci Tech Off Int Epiz 26:(2)511-517.
  852. Tizard I. 1990. Risks associated with the use of live vaccines. J Am Vet Med Assoc 196:1851-1858.
  853. Tizard I. 1991. Use of immunomodulators as an aid to clinical management of feline leukemia virus-infected cats. J Am Vet Med Assoc 199:1482-1487.
  854. Tizard I, Bass EP. 1991. Evaluation of a killed whole virion feline leukemia virus vaccine. J Am Vet Med Assoc 199:1410-1413.
  855. Tizard I, Ni Y. 1998. Use of serologic testing to assess immune status of companion animals. J Am Vet Med Assoc 213:54-60.
  856. Torres B, Elyar JS, Okada S, et al. 1997. Fundamentals of FIV infection: is a vaccine possible? Feline Pract 25:6-12.
  857. Torres AN, O’Halloran KP, Larson RD, et al. 2009. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet Immunol Immunopathol 1-37.
  858. Torres AN, O’Halloran KP, Larson LJ, et al. 2010. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet Immunol Immunopathol 134:122-131.
  859. Toshach K, Jackson M, Dubielzig RR. 1997. Hepatocellular necrosis associated with the subcutaneous injection of an intranasal Bordetella bronchiseptica-canine parainfluenza vaccine. J Am Anim Hosp Assoc 33:126-128.
  860. Tronel JP, Bey RF, Thevenon J, et al. 1999. Efficacy of Leptodog vaccine in dogs demonstrated by experimental challenges: evaluation at short term and duration of immunity. In Proceedings of the 24th World Small Animal Veterinary Congress, Lyon, France, Sept 23-26.
  861. Troy GC, Becker MJ, Greene RT. 1996. Proficiency testing of selected antigen and antibody tests for use in dogs and cats. J Am Vet Med Assoc 209:914-917.
  862. Truyen U. 2006. Evolution of canine parvovirus—a need for new vaccines? Vet Microbiol 117:9-13.
  863. Truyen U, Addie D, Belak S, et al. 2009. Feline panleukopenia. ABCD guidelines on prevention and management. J Feline Med Surg 11:538-546.
  864. Truyen U, Evermann JF, Vieler E, et al. 1996. Evolution of canine parvovirus involved loss and gain of feline host range. Virology 215:186-189.
  865. Truyen U, Platzer G, Parrish C. 1996. Antigenic type distribution among canine parvoviruses in dogs and cats in Germany. Vet Rec 138:365-366.
  866. Turnbull FM, McIntyre PB, Achat HM, et al. 2002. National study of adverse reactions after vaccination with bacilli Calmette-Guérin. Clin Infect Dis 34:447-453.
  867. Turnquist SE, Ostlund E. 1997. Calicivirus outbreak with high mortality in a Missouri feline colony. J Vet Diagn Invest 9:195-198.
  868. Twark L, Dodds WJ. 2000. Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs. J Am Vet Med Assoc 217:1021-1024.
  869. Ueda Y, Sakurai T, Kasama K, et al. 1993. Pharmacokinetic properties of a recombinant feline interferon and its stimulatory effects on 2′,5′-oligoadenylate synthetase activity in the cat. J Vet Med Sci 55:1-6.
  870. Uhl EW, Harvey SB, Michel F, et al. 2010. Immunogenicity of avian H5N1 influenza virus recombinant vaccines in cats. Viral Immunol 23:221-226.
  871. Uhl EW, Martin M, Coleman JK, et al. 2008. Advances in FIV vaccine technology. Vet Immunol Immunopathol 123:65-80.
  872. USDA. 2002. Veterinary Services memorandum no. 800.202: General licensing considerations: efficacy studies. http://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_202.pdf. Accessed 7/28/11.
  873. USDA. 2010. Adverse event reporting. http://www.aphis.usda.gov/animal_health/vet_biologics/vb_adverse_event.shtml. Accessed 3/6/11.
  874. USDA. 2010. General licensing considerations: target animal safety (TAS) studies prior to product licensure—VICH guideline 44. http://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_207.pdf. Accessed 3/13/11.
  875. USDA. 2010. Import and export regulations. http://www.aphis.usda.gov/import_export/animals/animal_import/animal_imports_states.shtml. Accessed 3/13/11.
  876. USDA. 2011. http://www.usda.gov. Accessed 3/11/11.
  877. Van de Perre P. 2003. Transfer of antibody via mother's milk. Vaccine 21:3374-3376.
  878. Van Heerden J, Bingham J, van Vuuren M, et al. 2002. Clinical and serological response of wild dogs (Lycaon pictus) to vaccination against canine distemper, canine parvovirus infection and rabies. J S Afr Vet Assoc 73:8-12.
  879. Van Kampen KR. 1997. Immunotherapy and cytokines. Semin Vet Med Surg 12:186-192.
  880. Van Klink E. 2010. Travel with pets within the European Union. Tijdschr Diergeneeskd 135(14-15):583.
  881. Vasko KA, McMichael J, Smith B, et al. 1988. Use of an immunomodulating agent in the treatment of myofascial pain. Vet Rev 8:5.
  882. Veir JK, Knorr R, Cavadine C, et al. 2007. Effect of supplementation with Enterococcus faecium (SF68) on immune functions in cats. Vet Ther 8:229-238.
  883. Veir JK, Lappin MR, Dow SW. 2006. Evaluation of a novel immunotherapy for treatment of chronic rhinitis in cats. J Feline Med Surg 8:400-411.
  884. Vennema H, de Groot RJ, Harbour DA, et al. 1990. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 64:1407-1409.
  885. Vidor E. 2007. The nature and consequences of intra- and inter-vaccine interference. J Comp Pathol 137:S62-S66.
  886. Vitale CB, Gross TL, Magro CM. 1999. Vaccine-induced ischemic dermatopathy in the dog. Vet Dermatol 10:131-142.
  887. Walker RI, Blanchard T, Braun JM, et al. 2004. Meeting summary possibilities for active and passive vaccination against opportunistic infections. Vaccine 22:801-804.
  888. Wallace BL, McMillen JK. 1985. An inactivated canine parvovirus vaccine: duration of immunity and effectiveness in presence of maternal antibody. Canine Pract 12:14-19.
  889. Waner T, Mazar S, Nachmias E, et al. 2003. Evaluation of a dot ELISA kit for measuring immunoglobulin M antibodies to canine parvovirus and distemper virus. Vet Rec 152:588-591.
  890. Waner T, Naveh A, Wudovsky I, et al. 1996. Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic-based enzyme-linked immunosorbent assay. J Vet Diagn Invest 8:427-432.
  891. Wang C, Johnson CM, Ahluwalia SK, et al. 2010. Dual-emission fluorescence resonance energy transfer (FRET) real-time PCR differentiates feline immunodeficiency virus subtypes and discriminates infected from vaccinated cats. J Clin Microbiol 48:1667-1672.
  892. Ward MP, Guptill LF, Prahl A, et al. 2004. Serovar-specific prevalence and risk factors for leptospirosis among dogs: 90 cases (1997–2002). J Am Vet Med Assoc 224:1958-1963.
  893. Ward MP, Guptill LF, Wu CC. 2004. Evaluation of environmental risk factors for leptospirosis in dogs. 36 cases (1997–2002). J Am Vet Med Assoc 225:72-77.
  894. Wasmoen T, Chu HJ, Chavez L, et al. 1992. Demonstration of one-year duration of immunity for an inactivated feline Chlamydia psittaci vaccine. Feline Pract 20:13-16.
  895. Webster AC. 1975. The adverse effect of environment on the response to distemper vaccination. Aust Vet J 51:488-490.
  896. Weigland CM, Brewer WG. 1996. Vaccination site sarcomas in cats. Compend Contin Educ Pract Vet 18:869-878.
  897. Weiss ATA, Klopfleisch R, Gruber AD. 2010. Prevalence of feline leukaemia provirus DNA in feline lymphomas. J Feline Med Surg 12:929-935.
  898. Weiss RC, 1991. Feline infectious peritonitis: advances in therapy and control, pp 3-12. In Wolf AM, August JD (eds): Consultations in feline internal medicine, ed 2. WB Saunders, Philadelphia.
  899. Weiss RC, Cummins JM, Richards AB. 1991. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J Am Vet Med Assoc 199:1477-1481.
  900. Welter J, Taylor J, Tartaglia J, et al. 1999. Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection. Vaccine 17:308-318.
  901. Westhoff D, Orveillon FX, Farnow D, et al. 2010. Safety of a non-adjuvanted therapeutic vaccine for the treatment of feline dermatophytosis. Vet Rec 167:899-903.
  902. Weyer J, Rupprecht CE, Nel LH. 2009. Poxvirus-vectored vaccines for rabies—a review. Vaccine 27:7198-7201.
  903. Whittemore JC, Hawley JR, Jensen WA, et al. 2010. Antibodies against Crandell Rees feline kidney (CRFK) cell line antigens, a-enolase, and annexis A2 in vaccinated and CRFK hyperinoculated cats. J Vet Intern Med 24:306-313.
  904. Wilbur LA, Evermann JF, Levings RL, et al. 1994. Abortion and death in pregnant bitches associated with a canine vaccine contaminated with bluetongue. J Am Vet Med Assoc 204:1762-1765.
  905. Wilde H. 2001. What are today's orphaned vaccines? Clin Infect Dis 33:648-650.
  906. Wikle RE, Fretwell B, Jarecki M, et al. 2006. Canine Lyme disease: one-year duration of immunity elicited with a canine OspA monovalent Lyme vaccine. Int J Appl Res Vet Med 4:23-28.
  907. Williams J, Laris R, Gray AW, et al. 2002. Studies of the efficacy of a novel intranasal vaccine against feline bordetellosis. Vet Rec 150:439-442.
  908. Wills C. 2000. How we defend ourselves against infectious diseases. ASM News 66:523-530.
  909. Wilson PJ, Oertli EH, Hunt PR, et al. 2010. Evaluation of a postexposure rabies prophylaxis protocol for domestic animals in Texas: 2000–2009. J Am Vet Med Assoc 237:1395-1401.
  910. Wilson RB, Holladay JA, Cave JS. 1986. A neurologic syndrome associated with use of a canine coronavirus-parvovirus vaccine in dogs. Compend Contin Educ Pract Vet 8:117-122.
  911. Wimsatt J, Jay MT, Innes KE, et al. 2001. Serologic evaluation, efficacy, and safety of a commercial modified-live canine distemper vaccine in domestic ferrets. Am J Vet Res 62:736-740.
  912. Wolf AM. 1999. Recommendations are not so ivory-tower. Vet Forum Aug:12-15.
  913. Woo EJ, Burwen DR, Gatumu SN, et al. 2003. Extensive limb swelling after immunization. Reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis 37:351-358.
  914. Wood JLN, Adams VJ. 2006. Epidemiological approaches to safety in investigations. Vet Microbiol 117:66-70.
  915. Woolhouse ME, Haydon DT, Bundy DA. 1997. The design of veterinary vaccination programs. Vet J 153:41-47.
  916. Wynn SG. 1998. Studies on use of homeopathy in animals. J Am Vet Med Assoc 212:719-724.
  917. Wynn SG, Dodds WJ. 1995. Vaccine-associated disease in a family of young Akita dogs, pp 81-84. In Proceedings of the Annual Conference of the American Holistics Veterinary Medicine Association, Snowmass, CO.
  918. Yamamoto JK, Sanou MP, Abbott JR, et al. 2010. Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res 8:14-25.
  919. Yanai T, Fujishima N, Fukushi H, et al. 2003. Experimental infection of equine herpesvirus 9 in dogs. Vet Pathol 40:263-267.
  920. Yarwood J. 2006. Communicating vaccine benefit and risk—lessons from the medical field. Vet Microbiol 117:71-74.
  921. Yates KM, Rosenberg LJ, Harris CK, et al. 1992. Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus. Vet Immunol Immunopathol 35:177-189.
  922. Yilma T. 1994. Genetically engineered vaccines for animal viral diseases. J Am Vet Med Assoc 204:1606-1615.
  923. Yokoyama N, Fujita K, Damiani A, et al. 1998. Further development of a recombinant feline herpesvirus type 1 vector expressing feline calicivirus immunogenic antigen. J Vet Med Sci 60:717-723.
  924. Yokoyama N, Maeda N, Mikami T. 1997. Recombinant viral vector vaccines for the veterinary use. J Vet Med Sci 59:311-322.
  925. Yoshikawa R, Sato E, Igarashi T, et al. 2010. Characterization of RD-114 virus isolated from a commercial canine vaccine manufactured using CRFK cells. J Clin Microbiol 48:3366-3369.
  926. Zanoni RG, Bugnon P, Deranleau E, et al. 2010. Walking the dog and moving the cat: rabies serology in the context of international pet travel schemes. Schweiz Arch Tierheilkd 152:561-568.
  927. Zeidner N. 1990. Alpha interferon 2b in combination with zidovudine for treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 34:1749-1756.
  928. Zwahlen RD, Spreng D, Wyder-Walther M. 1994. In vitro and in vivo activity of human interleukin-8 in dogs. Vet Pathol 31:61-66.
  929. Zwijnenberg R. 2003. The recent availability in Australia of a vaccine to protect dogs against both coronavirus and Leptospira icterohaemorrhagiae. Aust Vet J 81:731.